<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair - Forster, R - 2016 | Cochrane Library</title> <meta content="Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair - Forster, R - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004179.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair - Forster, R - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004179.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004179.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair" name="citation_title"/> <meta content="Rachel Forster" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="rbedenis@gmail.com" name="citation_author_email"/> <meta content="Marlene Stewart" name="citation_author"/> <meta content="University of Edinburgh" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD004179.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/03/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004179.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004179.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004179.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [*therapeutic use]; Arthroplasty, Replacement, Hip [*adverse effects]; Arthroplasty, Replacement, Knee [*adverse effects]; Hemorrhage [chemically induced]; Heparin [*therapeutic use]; Hip Fractures [*surgery]; Randomized Controlled Trials as Topic; Venous Thromboembolism [*prevention &amp; control]; Vitamin K [*antagonists &amp; inhibitors]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004179.pub2&amp;doi=10.1002/14651858.CD004179.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="jU9oKp1Y";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004179\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004179\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004179.pub2",title:"Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair",firstPublishedDate:"Mar 30, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004179.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004179.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004179.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004179.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004179.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004179.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004179.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004179.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004179.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004179.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12197 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004179.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-sec-0168"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-sec-0059"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-sec-0162"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/appendices#CD004179-sec-0173"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/table_n/CD004179StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/table_n/CD004179StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/information#CD004179-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rachel Forster</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004179.pub2/information#CD004179-cr-0003">Marlene Stewart</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/information/en#CD004179-sec-0186">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 March 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004179.pub2">https://doi.org/10.1002/14651858.CD004179.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004179-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004179-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004179-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004179-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004179-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004179-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004179-abs-0001" lang="en"> <section id="CD004179-sec-0001"> <h3 class="title" id="CD004179-sec-0001">Background</h3> <p>The optimal duration of thromboprophylaxis after total hip or knee replacement, or hip fracture repair remains controversial. It is common practice to administer prophylaxis using low‐molecular‐weight heparin (LMWH) or unfractionated heparin (UFH) until discharge from hospital, usually seven to 14 days after surgery. International guidelines recommend extending thromboprophylaxis for up to 35 days following major orthopaedic surgery but the recommendation is weak due to moderate quality evidence. In addition, recent oral anticoagulants that exert effect by direct inhibition of thrombin or activated factor X lack the need for monitoring and have few known drug interactions. Interest in this topic remains high. </p> </section> <section id="CD004179-sec-0002"> <h3 class="title" id="CD004179-sec-0002">Objectives</h3> <p>To assess the effects of extended‐duration anticoagulant thromboprophylaxis for the prevention of venous thromboembolism (VTE) in people undergoing elective hip or knee replacement surgery, or hip fracture repair. </p> </section> <section id="CD004179-sec-0003"> <h3 class="title" id="CD004179-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Specialised Register (last searched May 2015) and CENTRAL (2015, Issue 4). Clinical trials databases were searched for ongoing or unpublished studies. </p> </section> <section id="CD004179-sec-0004"> <h3 class="title" id="CD004179-sec-0004">Selection criteria</h3> <p>Randomised controlled trials assessing extended‐duration thromboprophylaxis (five to seven weeks) using accepted prophylactic doses of LMWH, UFH, vitamin K antagonists (VKA) or direct oral anticoagulants (DOAC) compared with short‐duration thromboprophylaxis (seven to 14 days) followed by placebo, no treatment or similar extended‐duration thromboprophylaxis with LMWH, UFH, VKA or DOACs in participants undergoing hip or knee replacement or hip fracture repair. </p> </section> <section id="CD004179-sec-0005"> <h3 class="title" id="CD004179-sec-0005">Data collection and analysis</h3> <p>We independently selected trials and extracted data. Disagreements were resolved by discussion. We performed fixed‐effect model meta‐analyses with odds ratios (ORs) and 95% confidence intervals (CIs). We used a random‐effects model when there was heterogeneity. </p> </section> <section id="CD004179-sec-0006"> <h3 class="title" id="CD004179-sec-0006">Main results</h3> <p>We included 16 studies (24,930 participants); six compared heparin with placebo, one compared VKA with placebo, two compared DOAC with placebo, one compared VKA with heparin, five compared DOAC with heparin and one compared anticoagulants chosen at investigators' discretion with placebo. Three trials included participants undergoing knee replacement. No studies assessed hip fracture repair. </p> <p>Trials were generally of good methodological quality. The main reason for unclear risk of bias was insufficient reporting. The quality of evidence according to GRADE was generally moderate, as some comparisons included a single study, low number of events or heterogeneity between studies leading to wide CIs. </p> <p>We showed no difference between extended‐duration heparin and placebo in symptomatic VTE (OR 0.59, 95% CI 0.35 to 1.01; 2329 participants; 5 studies; high quality evidence), symptomatic deep vein thrombosis (DVT) (OR 0.73, 95% CI 0.39 to 1.38; 2019 participants; 4 studies; moderate quality evidence), symptomatic pulmonary embolism (PE) (OR 0.61, 95% CI 0.16 to 2.33; 1595 participants; 3 studies; low quality evidence) and major bleeding (OR 0.59, 95% CI 0.14 to 2.46; 2500 participants; 5 studies; moderate quality evidence). Minor bleeding was increased in the heparin group (OR 2.01, 95% CI 1.43 to 2.81; 2500 participants; 5 studies; high quality evidence). Clinically relevant non‐major bleeding was not reported. </p> <p>We showed no difference between extended‐duration VKA and placebo (one study, 360 participants) for symptomatic VTE (OR 0.10, 95% CI 0.01 to 1.94; moderate quality evidence), symptomatic DVT (OR 0.13, 95% CI 0.01 to 2.62; moderate quality evidence), symptomatic PE (OR 0.32, 95% CI 0.01 to 7.84; moderate quality evidence) and major bleeding (OR 2.89, 95% CI 0.12 to 71.31; low quality evidence). Clinically relevant non‐major bleeding and minor bleeding were not reported. </p> <p>Extended‐duration DOAC showed reduced symptomatic VTE (OR 0.20, 95% CI 0.06 to 0.68; 2419 participants; 1 study; moderate quality evidence) and symptomatic DVT (OR 0.18, 95% CI 0.04 to 0.81; 2459 participants; 2 studies; high quality evidence) compared to placebo. No differences were found for symptomatic PE (OR 0.25, 95% CI 0.03 to 2.25; 1733 participants; 1 study; low quality evidence), major bleeding (OR 1.00, 95% CI 0.06 to 16.02; 2457 participants; 1 study; low quality evidence), clinically relevant non‐major bleeding (OR 1.22, 95% CI 0.76 to 1.95; 2457 participants; 1 study; moderate quality evidence) and minor bleeding (OR 1.18, 95% CI 0.74 to 1.88; 2457 participants; 1 study; moderate quality evidence). </p> <p>We showed no difference between extended‐duration anticoagulants chosen at investigators' discretion and placebo (one study, 557 participants, low quality evidence) for symptomatic VTE (OR 0.50, 95% CI 0.09 to 2.74), symptomatic DVT (OR 0.33, 95% CI 0.03 to 3.21), symptomatic PE (OR 1.00, 95% CI 0.06 to 16.13), and major bleeding (OR 5.05, 95% CI 0.24 to 105.76). Clinically relevant non‐major bleeding and minor bleeding were not reported. </p> <p>We showed no difference between extended‐duration VKA and heparin (one study, low quality evidence) for symptomatic VTE (OR 1.64, 95% CI 0.85 to 3.16; 1279 participants), symptomatic DVT (OR 1.36, 95% CI 0.69 to 2.68; 1279 participants), symptomatic PE (OR 9.16, 95% CI 0.49 to 170.42; 1279 participants), major bleeding (OR 3.87, 95% CI 1.91 to 7.85; 1272 participants) and minor bleeding (OR 1.33, 95% CI 0.64 to 2.76; 1279 participants). Clinically relevant non‐major bleeding was not reported. </p> <p>We showed no difference between extended‐duration DOAC and heparin for symptomatic VTE (OR 0.70, 95% CI 0.28 to 1.70; 15,977 participants; 5 studies; low quality evidence), symptomatic DVT (OR 0.60, 95% CI 0.11 to 3.27; 15,977 participants; 5 studies; low quality evidence), symptomatic PE (OR 0.91, 95% CI 0.43 to 1.94; 14,731 participants; 5 studies; moderate quality evidence), major bleeding (OR 1.11, 95% CI 0.79 to 1.54; 16,199 participants; 5 studies; high quality evidence), clinically relevant non‐major bleeding (OR 1.08, 95% CI 0.90 to 1.28; 15,241 participants; 4 studies; high quality evidence) and minor bleeding (OR 0.95, 95% CI 0.82 to 1.10; 11,766 participants; 4 studies; high quality evidence). </p> </section> <section id="CD004179-sec-0007"> <h3 class="title" id="CD004179-sec-0007">Authors' conclusions</h3> <p>Moderate quality evidence suggests extended‐duration anticoagulants to prevent VTE should be considered for people undergoing hip replacement surgery, although the benefit should be weighed against the increased risk of minor bleeding. Further studies are needed to better understand the association between VTE and extended‐duration oral anticoagulants in relation to knee replacement and hip fracture repair, as well as outcomes such as distal and proximal DVT, reoperation, wound infection and healing. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004179-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004179-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004179-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD004179-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004179-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD004179-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD004179-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD004179-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004179-abs-0003" lang="en"> <h3>Anticoagulants taken for longer periods to prevent deep vein thrombosis or pulmonary embolism after hip or knee replacement </h3> <p><b>Background</b> </p> <p>Patients undergoing surgery have an increased risk of developing blood clots in their veins. These clots may be in the deep veins of the leg (deep vein thrombosis (DVT)) or travel to the lungs (pulmonary embolism (PE)). Venous thromboembolism (VTE) is the combined term for DVT and PE. Prevention of these blood clots (prophylaxis) after surgery may reduce the risk of postoperative vein clots. These potential benefits, however, have to be balanced against the associated risks of bleeding. The optimal duration of prophylaxis after total hip or knee replacement, or hip fracture repair remains controversial. It is common practice to administer prophylaxis using drugs such as low‐molecular‐weight heparin and unfractionated heparin (anticoagulants) until discharge from hospital and for a minimum of seven to 14 days after surgery. Current international guidelines recommend extending prophylaxis for up to 35 days following major orthopaedic surgery but recognise that the recommendation is weak due to moderate quality evidence. In addition, new oral anticoagulants (direct oral anticoagulants (DOAC)) show potential benefits such as taking tablets by mouth instead of injection, lack of frequent monitoring and few known drug interactions. Interest in this topic therefore remains high. </p> <p><b>Study characteristics and key results</b> </p> <p>A total of 16 studies were included, with 24,930 randomised participants (current until May 2015). The main outcomes of interest were symptomatic (showing symptoms) VTE, including DVT and PE, and bleeding (major, clinically relevant non‐major and minor bleeding). Six studies compared heparin with placebo, one compared the vitamin K antagonist (VKA) warfarin with placebo, two compared DOAC with placebo, one compared VKA with heparin, five compared DOAC with heparin and one study compared using a variety of anticoagulant treatments with placebo. Only three trials included participants undergoing knee replacement and no studies included participants undergoing hip fracture repair. </p> <p>For the comparison heparin versus placebo (six studies) no differences were found between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE and major bleeding. Minor bleeding was increased in the heparin group. Clinically relevant non‐major bleeding was not reported. </p> <p>The comparison VKA versus placebo (one study) and the comparison placebo with anticoagulants chosen at the discretion of the investigators (one study) showed no differences between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE and major bleeding. Clinically relevant non‐major bleeding and minor bleeding were not reported. </p> <p>For the comparison DOACs versus placebo (two studies), reduced symptomatic VTE and symptomatic DVT were found in favour of the DOAC but no differences were found for symptomatic PE, major bleeding, clinically relevant non‐major bleeding and minor bleeding. </p> <p>Comparing extended‐duration VKA with extended‐duration LMWH (one study) there was no difference between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE, major bleeding and minor bleeding. Clinically relevant non‐major bleeding was not reported. </p> <p>Comparing extended‐duration DOAC with extended‐duration LMWH (five studies) there was no difference between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE, major bleeding, clinically relevant non‐major bleeding and minor bleeding. </p> <p><b>Quality of the evidence</b> </p> <p>Overall, the included studies were of good methodological quality, with the majority of studies having little risk of bias due to study design and reporting. The majority of concerns came from lack of reporting of specific details. The quality of the evidence was generally moderate, either because only one study was included in a comparison, because of few events or because there were a lot of differences between the findings of the studies meaning that the data were difficult to interpret. Further studies are needed to better understand the relationship between VTE and extended‐duration oral anticoagulants for knee replacement and hip fracture repair as well as outcomes such as DVT below the knee and above the knee, reoperation, wound infection and healing. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004179-sec-0168" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004179-sec-0168"></div> <h3 class="title" id="CD004179-sec-0169">Implications for practice</h3> <section id="CD004179-sec-0169"> <p>Extended‐duration thromboprophylaxis should be considered for people undergoing hip or knee replacement, but the risk of increased minor bleeding should be carefully considered. </p> </section> <h3 class="title" id="CD004179-sec-0170">Implications for research</h3> <section id="CD004179-sec-0170"> <p>Continued research in this area is needed, specifically as newer, and possibly safer medications become available. Oral anticoagulants could be a promising alternative to LMWHs that require daily injections, but the evidence is currently insufficient. Specifically, further research is required to better understand the association between VTE and extended‐duration oral anticoagulants in relation to knee replacement and hip fracture repair as well as outcomes such as distal and proximal DVT, reoperation, wound infection and healing, regarding the optimal duration of extended therapy, possibility of combining therapies and effects of extended therapies on length of hospital stay. An assessment of cost‐effectiveness as part of the further research is also warranted. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD004179-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD004179-sec-0029"></div> <div class="table" id="CD004179-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> heparin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with heparin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.59<br/> (0.35 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2329<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (12 to 33) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.73<br/> (0.39 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2019<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (9 to 33) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.61<br/> (0.16 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1595<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (1 to 15) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.59<br/> (0.14 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2500<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 9) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant non‐major bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ minor<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.01<br/> (1.43 to 2.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2500<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000<br/> (65 to 119) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, low number of events leading to imprecision of results<br/> <sup>2</sup> Downgraded by one level, some heterogeneity present (I<sup>2</sup> = 49%) leading to wide CIs </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004179-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> vitamin K antagonists<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin K antagonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.10<br/> (0.01 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 43) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.13<br/> (0.01 to 2.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 43) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.32<br/> (0.01 to 7.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 43) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 2.89<br/> (0.12 to 71.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no events recorded in placebo group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant non‐major bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, results from a single study only so heterogeneity could not be assessed<br/> <sup>2</sup> Downgraded by one level, number of events small leading to wide CI and imprecision of results </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004179-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> DOAC<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DOAC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.20<br/> (0.06 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2419<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 8) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.18<br/> (0.04 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2459<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 7) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.25<br/> (0.03 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1733<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/> (0 to 10) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/> (0.06 to 16.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2457<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/> (0 to 13) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding‐ clinically relevant non‐major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.22<br/> (0.76 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2457<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (21 to 51) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ minor<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.18<br/> (0.74 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2457<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (21 to 51) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DOAC:</b> direct oral anticoagulant; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, results from a single study so heterogeneity cannot be assessed<br/> <sup>2</sup> Downgraded by one level, low number of events leading to wide CI and imprecision of results </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004179-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> anticoagulant (chosen at investigators' discretion)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anticoagulant (chosen at investigators' discretion)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.50<br/> (0.09 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>557<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.33<br/> (0.03 to 3.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>557<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (0 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/> (0.06 to 16.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>557<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (0 to 55) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 5.05<br/> (0.24 to 105.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>557<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no major bleeding recorded in the placebo groups</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant non‐major bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, results from a single study so heterogeneity could not be assessed<br/> <sup>2</sup> Downgraded by one level, low number of events leading to wide CIs and imprecision of results </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004179-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> vitamin K antagonists<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin K antagonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.64<br/> (0.85 to 3.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1279<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/> (20 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.36<br/> (0.69 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1279<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000<br/> (16 to 60) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 9.16<br/> (0.49 to 170.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1279<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no cases of symptomatic PE reported in the heparin study arm</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.87<br/> (1.91 to 7.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1272<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (30 to 111) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding ‐ clinically indicated non‐major</p> <p>Treatment duration 28 ‐ 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinically indicated non‐major bleeding events not reported in single included study in this comparison </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ minor<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.33<br/> (0.64 to 2.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1279<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (13 to 54) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VKA:</b> vitamin K antagonist; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, single study so heterogeneity could not be assessed<br/> <sup>2</sup> Downgraded by one level, wide CI<br/> <sup>3</sup> Downgraded by one level, low number of events leading to imprecision of results </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD004179-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> DOAC<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DOAC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.70<br/> (0.28 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15977<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 8) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)</p> <p>Treatment duration 28 ‐ 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.60<br/> (0.11 to 3.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15977<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 9) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.91<br/> (0.43 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14731<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (1 to 4) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ major</p> <p>Treatment duration 28 ‐ 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.11<br/> (0.79 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16199<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (7 to 13) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ clinically relevant, non‐major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.08<br/> (0.90 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15241<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/> (30 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ minor</p> <p>Treatment duration 28 ‐ 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.95<br/> (0.82 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11766<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/> (55 to 72) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DOAC:</b> direct oral anticoagulant; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for inconsistency (heterogeneity, I<sup>2</sup> = 55%)<br/> <sup>2</sup> Downgraded by one level for imprecision due to low number of events leading to wide CI<br/> <sup>3</sup> Downgraded by one level for inconsistency (heterogeneity, I<sup>2</sup> = 65%) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004179-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004179-sec-0030"></div> <section id="CD004179-sec-0031"> <h3 class="title" id="CD004179-sec-0031">Description of the condition</h3> <p>Venous thromboembolism describes the formation of a clot in the deep veins (deep vein thrombosis or DVT ‐ usually of the lower extremities) and the subsequent embolisation of the clot to the pulmonary circulation (pulmonary embolisation or PE) or both. DVT of the lower limbs is associated with localised pain, swelling and erythema as well as the development of pulmonary emboli (PE), and the more localised and chronic post thrombotic syndrome. PE presents with shortness of breath, pain on inspiration, tachycardia and right heart overload, and if untreated, can lead to circulatory collapse and death. </p> <p>The incidence of VTE, in mostly white populations, is between 100 and 200 per 100,000 person years (<a href="./references#CD004179-bbs2-0032" title="HeitJA . Epidemiology of venous thromboembolism. Nature Reviews Cardiology2015;12:464–74. [DOI: 10.1038/nrcardio.2015.83] ">Heit 2015</a>; <a href="./references#CD004179-bbs2-0048" title="WhiteRH . The epidemiology of venous thromboembolism. Circulation2003;107:I‐4–I‐8. ">White 2003</a>). Of these, it is estimated that 45 to 117 per 100,000 person years are due to DVT (without PE) and 29 to 78 per 100,000 person years are due to PE (with or without DVT) (<a href="./references#CD004179-bbs2-0032" title="HeitJA . Epidemiology of venous thromboembolism. Nature Reviews Cardiology2015;12:464–74. [DOI: 10.1038/nrcardio.2015.83] ">Heit 2015</a>). Recurrent VTE occurs in approximately 7.4% of patients by one year, rising to 30.4% of patients by 10 years (<a href="./references#CD004179-bbs2-0025" title="CushmanM . Epidemiology and risk factors for venous thrombosis. Seminars in Hematology2007;44(2):62‐9. ">Cushman 2007</a>; <a href="./references#CD004179-bbs2-0032" title="HeitJA . Epidemiology of venous thromboembolism. Nature Reviews Cardiology2015;12:464–74. [DOI: 10.1038/nrcardio.2015.83] ">Heit 2015</a>; <a href="./references#CD004179-bbs2-0048" title="WhiteRH . The epidemiology of venous thromboembolism. Circulation2003;107:I‐4–I‐8. ">White 2003</a>). </p> <p>Although DVT and PE can occur spontaneously, there are many risk factors for VTE, including periods of inactivity, dehydration, hospitalisation, trauma, clotting disorders and previous thrombosis, varicose veins with phlebitis, pregnancy, oral combined hormonal contraceptives, malignancy, obesity, smoking and age (<a href="./references#CD004179-bbs2-0040" title="National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods evidence and guidance. http://www.nice.org.uk/guidance/cg92/evidence/cg92‐venous‐thromboembolism‐reducing‐the‐risk‐full‐guideline3 (accessed September 2015). ">NICE 2010</a>). </p> <p>Prophylactic strategies in those deemed to be at risk (for example those undergoing surgical procedures or prolonged hospital inpatient stays) are recommended by international guidelines published by the National Institute for Health and Care Excellence (NICE) (<a href="./references#CD004179-bbs2-0040" title="National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods evidence and guidance. http://www.nice.org.uk/guidance/cg92/evidence/cg92‐venous‐thromboembolism‐reducing‐the‐risk‐full‐guideline3 (accessed September 2015). ">NICE 2010</a>; <a href="./references#CD004179-bbs2-0041" title="National Clinical Guideline Centre. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical Guideline. Methods, evidence and recommendations. http://www.nice.org.uk/guidance/cg144/evidence/cg144‐venous‐thromboembolic‐diseases‐full‐guideline3 (accessed September 2015). ">NICE 2012</a>), The American College of Chest Physicians (ACCP) (<a href="./references#CD004179-bbs2-0031" title="GuyattGH , AklEA , CrowtherM , GuttermanDD , SchuünemannHJ , American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):7S‐47S. [DOI: 10.1378/chest.1412S3] ">Guyatt 2012</a>) and the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="./references#CD004179-bbs2-0045" title="Scottish Intercollegiate Guidelines Network. Thrombosis Guidelines Prevention and management of venous thromboembolism. A national clinical guideline. http://www.sign.ac.uk/pdf/sign122.pdf (accessed September 2015). ">SIGN 2010</a>) and include the use of anticoagulation such as LMWH, UFH, oral direct factor Xa inhibitor (rivaroxaban), oral direct thrombin inhibitor (dabigatran), pentasaccharides (fondaparinux), and mechanical compression such as compression stockings and intermittent pneumatic compression devices. </p> </section> <section id="CD004179-sec-0032"> <h3 class="title" id="CD004179-sec-0032">Description of the intervention</h3> <p>It is common practice to administer prophylaxis until discharge from hospital, and for a minimum of seven to 14 days after surgery. However, in patients receiving in‐hospital prophylaxis, the prevalence of venographic DVT (a blood clot in the leg detected by venography) is still 15% to 30% at the time of hospital discharge (<a href="./references#CD004179-bbs2-0029" title="ErikssonBI , Wille‐JorgensenP , KaleboP , MouretP , RosencherN , BoschP , et al. A comparison of recombinant hirudin with a low‐molecular‐weight heparin to prevent thromboembolic complications after total hip replacement [see comments]. New England Journal of Medicine1997;337(19):1329‐35. ">Eriksson 1997</a>; <a href="./references#CD004179-bbs2-0039" title="MohrDN , SilversteinMD , MurtaughPA , HarrisonJM . Prophylactic agents for venous thrombosis in elective hip surgery: Meta‐analysis of studies using venographic assessment. Archives of Internal Medicine1993;153(19):2221‐8. ">Mohr 1993</a>; <a href="./references#CD004179-bbs2-0042" title="NurmohamedMT , RosendaalFR , BullerHR , DekkerE , HommesDW , VandenbrouckeJP , et al. Low‐molecular‐weight heparin versus standard heparin in general and orthopaedic surgery: a meta‐analysis. Lancet1992;340(8812):152‐6. ">Nurmohamed 1992</a>) while an additional 10% to 25% of patients develop new asymptomatic DVT during the next three to four weeks (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0035" title="HirshJ . Evidence for the needs of out‐of‐hospital thrombosis prophylaxis: introduction. Chest1998;114(2 Suppl Evidence):113S‐4S. ">Hirsh 1998</a>). It is estimated, based on the available literature, that fewer than 10% of patients with venographically documented DVT will develop symptomatic VTE. </p> <p>Extended‐duration prophylaxis is prophylaxis which starts at admission and continues well beyond discharge, typically for an additional 21 to 28 days after discharge, leading to a period of prophylaxis of approximately 35 days (<a href="./references#CD004179-bbs2-0040" title="National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods evidence and guidance. http://www.nice.org.uk/guidance/cg92/evidence/cg92‐venous‐thromboembolism‐reducing‐the‐risk‐full‐guideline3 (accessed September 2015). ">NICE 2010</a>). Randomised trials have demonstrated that extending prophylaxis beyond the time of hospital discharge substantially reduces the risk of developing new asymptomatic thrombi at 30 to 45 days (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>) and this has led these investigators to recommend that prophylaxis of longer duration should be used in all patients undergoing total hip replacement (THR). </p> <p>However, two prospective studies, conducted in patients without known proximal DVT at the time of discharge from hospital, demonstrated that the incidence of new out‐of‐hospital symptomatic DVT or pulmonary embolism (PE) without extended‐duration prophylaxis was only approximately 2% after three months of follow‐up (<a href="./references#CD004179-bbs2-0037" title="LeclercJR , GentM , HirshJ , GeertsWH , GinsbergJS . The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. Chest1998;114(2 Suppl II):115S‐8S. ">Leclerc 1998</a>; <a href="./references#CD004179-bbs2-0044" title="RobinsonKS , AndersonDR , GrossM , PetrieD , LeightonR , StanishW , et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post‐arthroplasty screening study. A randomized, controlled trial. Annals of Internal Medicine1997;127(6):439‐45. ">Robinson 1997</a>). This data suggest that the majority of asymptomatic thrombi remain clinically silent irrespective of whether extended‐duration prophylaxis is given. Meanwhile, the impact of extended‐duration prophylaxis on symptomatic VTE remains to be clarified. <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a> showed that a significant reduction in symptomatic VTE could not be demonstrated and therefore concluded that prophylaxis confined to the in‐hospital phase is adequate in most patients. </p> </section> <section id="CD004179-sec-0033"> <h3 class="title" id="CD004179-sec-0033">Why it is important to do this review</h3> <p>Current ACCP and NICE guidelines (<a href="./references#CD004179-bbs2-0031" title="GuyattGH , AklEA , CrowtherM , GuttermanDD , SchuünemannHJ , American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):7S‐47S. [DOI: 10.1378/chest.1412S3] ">Guyatt 2012</a>; <a href="./references#CD004179-bbs2-0040" title="National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods evidence and guidance. http://www.nice.org.uk/guidance/cg92/evidence/cg92‐venous‐thromboembolism‐reducing‐the‐risk‐full‐guideline3 (accessed September 2015). ">NICE 2010</a>) for the prevention of VTE recommend extending thromboprophylaxis for up to 35 days following major orthopaedic surgery but recognise that the recommendation is weak due to moderate quality evidence (<a href="./references#CD004179-bbs2-0031" title="GuyattGH , AklEA , CrowtherM , GuttermanDD , SchuünemannHJ , American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest2012;141(2 Suppl):7S‐47S. [DOI: 10.1378/chest.1412S3] ">Guyatt 2012</a>). In addition, recent oral anticoagulants that exert effect by direct inhibition of thrombin or activated factor X lack the need for monitoring and have few known drug interactions. Differences between anticoagulants for the extended duration also warrant further investigation. Interest in this topic therefore remains high. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004179-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004179-sec-0034"></div> <p>To assess the effects of extended‐duration anticoagulant thromboprophylaxis for the prevention of venous thromboembolism (VTE) in people undergoing elective hip or knee replacement surgery, or hip fracture repair. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004179-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004179-sec-0035"></div> <section id="CD004179-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004179-sec-0037"> <h4 class="title">Types of studies</h4> <p>Randomised controlled studies which assessed extended duration of anticoagulant thromboprophylaxis for the prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. </p> <p>We defined extended‐duration thromboprophylaxis as thromboprophylaxis of duration of five to seven weeks. </p> <p>We included studies which used objective methods (e.g. ultrasound, venogram, V‐Q scan) to confirm the diagnosis of symptomatic and asymptomatic VTE (DVT or PE). We included data on asymptomatic DVT from these studies only if screening was performed using ascending lower‐limb contrast venography. We included open‐label, as well as double‐blind studies. </p> </section> <section id="CD004179-sec-0038"> <h4 class="title">Types of participants</h4> <p>Patients undergoing elective total hip or knee replacement surgery or hip fracture repair. Patients undergoing revisions of a previous hip or knee replacement were included. </p> </section> <section id="CD004179-sec-0039"> <h4 class="title">Types of interventions</h4> <p>We included studies which assessed extended‐duration thromboprophylaxis (five to seven weeks) using accepted prophylactic doses of anticoagulants LMWH, UFH, vitamin K antagonists or direct oral anticoagulants (DOACs) compared with short duration thromboprophylaxis therapy (seven to 14 days) followed by placebo or no treatment or similar extended duration of thromboprophylaxis therapy with anticoagulants LMWH, UFH, vitamin K antagonists or DOACs. Other antithrombotic therapy used in the prevention of VTE in major orthopaedic surgery was excluded. </p> </section> <section id="CD004179-sec-0040"> <h4 class="title">Types of outcome measures</h4> <section id="CD004179-sec-0041"> <h5 class="title">Primary outcomes</h5> <p>Symptomatic VTE (including DVT and PE)</p> </section> <section id="CD004179-sec-0042"> <h5 class="title">Secondary outcomes</h5> <p>Total VTE (symptomatic or asymptomatic)</p> <p>Asymptomatic DVT</p> <p>Asymptomatic proximal and distal DVT</p> <p>All‐cause mortality</p> <p>Adverse events</p> <p>Bleeding events (major, clinically relevant non‐major bleeding and minor bleeding)</p> <p>Reoperation</p> <p>Wound infection</p> <p>Wound healing</p> </section> </section> </section> <section id="CD004179-sec-0043"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004179-sec-0044"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (last searched May 2015) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2015, Issue 4, part of <i>The Cochrane Library</i>, <a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>. See <a href="./appendices#CD004179-sec-0174">Appendix 1</a> for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PVD/frame.html" target="_blank">Specialised Register</a> section of the Cochrane Vascular module in <i>The Cochrane Library</i> (<a href="http://www.cochranelibrary.com/" target="_blank">www.cochranelibrary.com</a>). </p> <p>The CIS searched the following trial databases for details of ongoing and unpublished studies; </p> <p>World Health Organization International Clinical Trials Registry <a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a> </p> <p>ClinicalTrials.gov <a href="http://clinicaltrials.gov/" target="_blank">http://clinicaltrials.gov/</a> </p> <p>ISRCTN Register <a href="http://www.isrctn.com/" target="_blank">http://www.isrctn.com/</a> </p> </section> <section id="CD004179-sec-0045"> <h4 class="title">Searching other resources</h4> <p>We searched references sections of relevant reports for further studies.</p> </section> </section> <section id="CD004179-sec-0046"> <h3 class="title" id="CD004179-sec-0046">Data collection and analysis</h3> <section id="CD004179-sec-0047"> <h4 class="title">Selection of studies</h4> <p>Studies identified in the search were individually evaluated by two review authors (RF and MS) based on title, abstract or full report for possible inclusion and any disagreements resolved by discussion. </p> </section> <section id="CD004179-sec-0048"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RF and MS) independently extracted data on study characteristics, efficacy and safety outcomes. Extracted information included study design, country, setting, intention‐to‐treat methods, number of participants randomised, number of participants excluded post‐randomisation, losses to follow up, age, sex, inclusion criteria, exclusion criteria, treatment and control details and duration of treatment, primary and secondary outcomes, funding, and how VTE outcomes were confirmed using objective methods. Data extracted for study outcomes included symptomatic VTE (DVT and PE), total VTE (symptomatic and asymptomatic), asymptomatic DVT documented by ascending lower limb contrast venography (stratified by proximal (popliteal vein and above) and distal (calf vein) DVT, where possible), all‐cause mortality, adverse events and bleeding events (major, clinically relevant non‐major and minor bleeding). We also extracted data for reoperation, wound infection and wound healing. We accepted the primary study authors' definitions for DVT, PE and bleeding events. Any disagreements were resolved through discussion. </p> </section> <section id="CD004179-sec-0049"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>RF and MS independently assessed the methodological quality of included studies using the 'Risk of bias' tool according to <a href="./references#CD004179-bbs2-0034" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>. The following domains were assessed: selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting) and other bias. We classified the domains as low risk, high risk, or unclear risk according to <a href="./references#CD004179-bbs2-0034" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>. Disagreements were resolved by discussion. </p> </section> <section id="CD004179-sec-0050"> <h4 class="title">Measures of treatment effect</h4> <p>We divided studies into six groups based on the treatment profile.</p> <p> <ol id="CD004179-list-0001"> <li> <p>Heparin (LMWH or UFH) versus placebo</p> </li> <li> <p>Vitamin K antagonists versus placebo</p> </li> <li> <p>DOACs versus placebo</p> </li> <li> <p>Anticoagulant chosen at investigators' discretion versus placebo</p> </li> <li> <p>Vitamin K antagonists versus heparin (LMWH or UFH)</p> </li> <li> <p>DOACs versus heparin (LMWH or UFH)</p> </li> </ol> </p> <p>We pooled data for each of the comparisons for the outcomes of symptomatic VTE, total VTE, asymptomatic DVT documented by ascending lower limb contrast venography, all‐cause mortality, adverse events, bleeding events, reoperation, wound infection and wound healing. The pooled data for each outcome were used to create a meta‐analysis by calculating odds ratios (ORs) with 95% confidence intervals (CIs), as all outcomes were dichotomous. We used fixed‐effect models, unless there was evidence of a large amount of heterogeneity (see <a href="#CD004179-sec-0053">Assessment of heterogeneity</a>), in which case a random‐effects model was implemented. </p> </section> <section id="CD004179-sec-0051"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual patient.</p> </section> <section id="CD004179-sec-0052"> <h4 class="title">Dealing with missing data</h4> <p>Where appropriate we used all randomised participants for the analysis. However, many of the included studies had many participants excluded after randomisation, creating a large disparity between the number of participants randomised and the number available for assessment of VTE at the end of the study. After discussion between the review authors, we decided it was generally inappropriate to include all randomised participants in our analysis, and would use the 'intention‐to‐treat' populations as reported by the studies. This population generally consisted of all participants that received treatment and had evaluable testing of VTE at the end of the study. If these values were not available, we utilised the reported per‐protocol data. Where necessary, we contacted study authors to provide missing data. </p> </section> <section id="CD004179-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. For each included meta‐analysis we obtained a value comparing the test statistic with a Chi<sup>2</sup> distribution. To help readers assess the consistency of results of studies in a meta‐analysis, Review Manager software (RevMan) (<a href="./references#CD004179-bbs2-0043" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) includes a method (I<sup>2</sup> statistic) that describes the percentage of total variation across studies due to heterogeneity rather than by chance. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity (<a href="./references#CD004179-bbs2-0033" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). For the purposes of this review, if a meta‐analysis was found to have an I<sup>2</sup> value of &gt; 50%, we calculated the ORs using a random‐effects model instead of a fixed‐effect model. </p> </section> <section id="CD004179-sec-0054"> <h4 class="title">Assessment of reporting biases</h4> <p>To detect reporting bias we planned to construct funnel plots for meta‐analyses that included at least 10 studies, as funnel plots with fewer than 10 studies lack the power to distinguish chance from real asymmetry (<a href="./references#CD004179-bbs2-0027" title="EggerM , DaveySG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.)1997;315(7109):629‐34. ">Egger 1997</a>). </p> </section> <section id="CD004179-sec-0055"> <h4 class="title">Data synthesis</h4> <p>We planned to use fixed‐effect models for each meta‐analysis to pool data, unless there was evidence of heterogeneity (see <a href="#CD004179-sec-0053">Assessment of heterogeneity</a>), in which case we planned to use a random‐effects model to derive the ORs and 95% CIs. </p> </section> <section id="CD004179-sec-0056"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We pre‐specified the following subgroup analyses for the primary outcome symptomatic VTE: </p> <p> <ol id="CD004179-list-0002"> <li> <p>hip replacement versus knee replacement versus hip fracture repair;</p> </li> <li> <p>according to duration of in‐hospital prophylaxis (up to 10 days, 10 to 14 days, 15 days or more) in trials comparing extended anticoagulant thromboprophylaxis versus placebo or no treatment; </p> </li> <li> <p>performing mandatory discharge venography versus not performing mandatory discharge venography in trials comparing extended anticoagulant thromboprophylaxis versus placebo or no treatment; </p> </li> <li> <p>patients undergoing revisions of a previous hip or knee replacement.</p> </li> </ol> </p> </section> <section id="CD004179-sec-0057"> <h4 class="title">Sensitivity analysis</h4> <p>We conducted sensitivity analyses to further explore the robustness of our results. To identify any study that may have exerted a disproportionate influence on the summary treatment effect, we removed studies from the analysis that accounted for over 50% of the weighted summary statistic, where three or more studies were included, to see if these heavily‐weighted studies altered the findings. We also planned to examine the effect of excluding studies that were at high risk of bias from the analysis, based on the 'Risk of bias' tool. We planned to carry out sensitivity analysis only when two or more studies remained in the analysis after the removal of the studies in question. </p> <section id="CD004179-sec-0058"> <h5 class="title">Summary of findings</h5> <p>We constructed a 'Summary of findings' table for each comparison using the GRADEpro GDT software (<a href="./references#CD004179-bbs2-0030" title="McMaster University (developed by Evidence Prime, Inc). Available from www.gradepro.org. GRADEpro Guideline Development Tool (GRADEpro GDT). McMaster University (developed by Evidence Prime, Inc). Available from www.gradepro.org, 2015. ">GRADEpro GDT 2015</a>) to present the main findings of the review. We included the outcomes symptomatic VTE, symptomatic DVT, symptomatic PE, major bleeding, clinically relevant non‐major bleeding and minor bleeding in the 'Summary of findings' table. We calculated assumed control intervention risks from the mean number of events in the control groups of the selected studies for each outcome. The system developed by the Grading of Recommendation, Assessment, Development and Evaluation Working Group (GRADE working group) was used for grading the quality of evidence as high, moderate, low and very low, based on within‐study risk of bias, directness of evidence, heterogeneity, precision of effects estimates, and risk of publication bias (<a href="./references#CD004179-bbs2-0024" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490‐4. ">Atkins 2004</a>). For completeness, additional 'Summary of findings' tables were created for the remaining outcomes of this review and presented in the appendices. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004179-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004179-sec-0059"></div> <section id="CD004179-sec-0060"> <h3 class="title">Description of studies</h3> <section id="CD004179-sec-0061"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD004179-fig-0001">Figure 1</a> </p> <div class="figure" id="CD004179-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD004179-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD004179-sec-0062"> <h4 class="title">Included studies</h4> <p>We included a total of 16 studies with 24,930 randomised participants (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a>; <a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>; <a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>; <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>). Nearly all the included randomised studies were multicentre, with just three recruiting from only a single centre (<a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>). Three studies were conducted in France (<a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a>), one study in Norway (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>), one in Denmark (<a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>), one in the US (<a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>) and another in the US and Canada (<a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>), one in Germany and Czech Republic (<a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>), one in Italy (<a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>), one in China (<a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>) and six that involved centres in multiple countries, ranging from 16 up to 27 countries (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>). The duration of treatment ranged between the studies, with the majority having treatment periods for an average of 35 days (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a>; <a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>). Both <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a> and <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a> had treatment periods of 28 to 35 days. One study had a four‐week post‐discharge period on top of a median nine‐day hospital phase (<a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>). Two studies had six‐week treatment periods (<a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a>), with the final study having a treatment period "up to 42 days" (<a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>). </p> <section id="CD004179-sec-0063"> <h5 class="title">Heparin versus placebo</h5> <p>A total of six trials with 3221 participants compared heparin with placebo (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>). Four of the studies evaluated participants undergoing total hip replacement (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>), two evaluated a combined group of hip and knee replacements (<a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>). <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a> presented results for the hip and knee replacement groups separately, while <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a> presented results for the combined group only. </p> <p>Five included studies evaluated LMWH versus placebo: three evaluated dalteparin (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>), one evaluated enoxaparin (<a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>) and one evaluated the certoparin (<a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>). <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a> compared the anticoagulant ardeparin sodium versus placebo. It should be noted that ardeparin has been removed from the market in the US since 2000, but not for reasons of efficacy or safety (<a href="./references#CD004179-bbs2-0026" title="Dotzel , MM . Determination that ardeparin sodium injection was not withdrawn from sale for reasons of safety or effectiveness. US Food and Drug Administration2002:http://www.fda.gov/ohrms/dockets/98fr/052302b.htm (date accessed September 2015). ">Dotzel 2002</a>). </p> <p>Duration of the in‐hospital/initial phase ranged from four days to 14 days. <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a> reported four to 10 days, while <a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a> and <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a> reported seven days for the initial phase. The <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a> and <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a> had 14 days for their initial phase. The <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a> did not report this timeframe. At the time of discharge from the hospital or at the end of the initial phase <a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>, <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a> and the <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a> had mandatory venography to test for DVT. The <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a> did state that they identified those with DVT at the end of the initial phase, but did not state their methods. While <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a> and <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a> did not use objective methods to test for DVT at the end of the initial phase of the trial. </p> </section> <section id="CD004179-sec-0064"> <h5 class="title">Vitamin K antagonists versus placebo</h5> <p>One trial with 360 participants compared the VKA antagonist warfarin with placebo (<a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>). <a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> evaluated participants undergoing total hip replacement. Duration of the in‐hospital/initial phase had a median of nine days (<a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>). At the time of discharge from the hospital <a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> performed ultrasonography on all participants to determine incidence of DVT before the second phase of the trial. </p> </section> <section id="CD004179-sec-0065"> <h5 class="title">DOACs versus placebo</h5> <p>Two trials with 2549 participants compared DOACs with placebo (<a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>). Both studies evaluated participants undergoing total hip replacement (<a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>). </p> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> compared the oral anticoagulant rivaroxaban with enoxaparin in the initial phase, then the enoxaparin group began taking placebo. <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> evaluated rivaroxaban compared with no treatment. Duration of the in‐hospital/initial phase was reported by <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> as seven days for the initial phase while <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> reported 10 to 14 days. At the end of the initial phase <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> performed ultrasonography on all participants to determine incidence of DVT before the second phase of the trial. The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> did not use objective methods to test for DVT at the end of the initial phase of the trial. </p> </section> <section id="CD004179-sec-0066"> <h5 class="title">Anticoagulant treatments chosen at the investigators' discretion versus placebo</h5> <p>One trial with 857 participants compared thromboprophylaxis using anticoagulant treatments chosen at the investigators' discretion with placebo in participants undergoing total knee replacement (<a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a>). The anticoagulation treatment was either heparin, enoxaparin, dalteparin, tinzaparin, nadroparin or fondaparinux (<a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a>). Duration of the in‐hospital/initial phase was reported as 10 days. At the end of the initial phase <a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> performed ultrasonography on all participants to determine incidence of DVT before the second phase of the trial. </p> </section> <section id="CD004179-sec-0067"> <h5 class="title">Vitamin K antagonists versus heparin</h5> <p>One study with a total of 1289 randomised participants evaluated acenocoumarol versus reviparin sodium (<a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a>). All participants began on the LMWH reviparin sodium until 3 ± 1 days after surgery when participants were randomised to either continue on reviparin sodium or cross over to acenocoumarol for six weeks. Participants showing clinical signs or symptoms of DVT, PE or major bleeding were not randomised. It is not clear whether those experiencing clinical signs or symptoms of DVT and PE at the randomisation stage underwent objective testing using venography or duplex scanning. The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> randomised participants undergoing a total hip replacement. </p> </section> <section id="CD004179-sec-0068"> <h5 class="title">DOACs versus heparin</h5> <p>Five studies with a total of 16,654 randomised participants evaluated DOAC versus heparin therapy (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>). All five studies evaluated participants undergoing a total hip replacement. One study compared apixaban versus enoxaparin (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>). One study evaluated ximelagatran versus enoxaparin (<a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>), although this study was terminated early due to safety concerns with ximelagatran. Two studies compared dabigatran etexilate with enoxaparin, one with two doses of dabigatran of 220 mg and 150 mg (<a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) and the other only evaluated the 220 mg dosage (<a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>). Rivaroxaban was compared to enoxaparin in one study (<a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>). As these five studies compared two different anticoagulant treatments and randomised participants prior to surgery, there was no initial phase and objective assessment of VTE after initial phase as seen in the studies described above comparing anticoagulants versus placebo. </p> </section> </section> <section id="CD004179-sec-0069"> <h4 class="title">Excluded studies</h4> <p>A total of seven studies were assessed as excluded (<a href="./references#CD004179-bbs2-0017" title="CompPC , SpiroTE , FriedmanRJ , WhitsettTL , JohnsonGJ , GardinerGA , et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. Journal of Bone &amp; Joint Surgery ‐ American Volume2001;83‐A(3):336‐45. SpiroTE . A double‐blind multicenter clinical trial comparing long term enoxaparin and placebo treatments in the prevention of venous thromboembolic disease after hip and knee replacement surgery. Blood. 1997; Vol. 90, issue Suppl 1:295a. ">Comp 2001</a>; <a href="./references#CD004179-bbs2-0018" title="NCT01720108 . Extended venous thromboembolism prophylaxis comparing rivaroxaban to aspirin following total hip and knee arthroplasty (EPCAT II). https://clinicaltrials.gov/ct2/show/NCT01720108 (accessed 30 August 2015). ">EPCAT II</a>; <a href="./references#CD004179-bbs2-0019" title="KristensenSS , PedersenP , PedersenNW , SchmidtSA , Kjaersgaard‐AndersenP . Combined treatment with indomethacin and low‐dose heparin after total hip replacement. Journal of Bone and Joint Surgery. American Volume1990;72:447‐9. ">Kristensen 1990</a>; <a href="./references#CD004179-bbs2-0020" title="ManganelliD , PazzagliM , MazzantiniD , PunziG , MancaM , VignaliC , et al. Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration1998;65(5):369‐74. PallaA , ManganelliD , RossiG . Prolonged prophylaxis with unfractioned heparin (UH) is effective to reduce delayed deep vein thrombosis (DVT) in total hip replacement (THR). European Respiratory Journal. 1997; Vol. 10, issue Suppl 25:5S. ">Manganelli 1998</a>; <a href="./references#CD004179-bbs2-0021" title="HaentjensP , DelinceP , The Belgian Nadroparin Post‐Hospital Discharge In Orthopedics (NPHDO) Study Group. Prevention of venous thromboembolism after hospital discharge. Continued pharmacologic prophylaxis versus no prophylaxis in patients undergoing total hip replacement. Hip International2001;11(1):25‐36. HaentjensP , The Belgian Nadroparin Post‐Hospital Discharge in Orthopedics (NPHDO) Study Group. Post‐hospital discharge prevention of deep vein thrombosis with nadroparin calcium after elective total hip replacement. British Journal of Anaesthesia1999;82(Suppl 1):78. The Belgian Nadroparin Post Hospital Discharge in Orthopedics (NPHDO) Study Group. Post hospital discharge prevention of deep vein thrombosis with nadroparin calcium after total hip arthroplasty. Haemostasis. 1998; Vol. 28, issue Suppl 2:292. ">NPHDO Study Group</a>; <a href="./references#CD004179-bbs2-0022" title="Anon . A multicenter, multinational, randomized, double‐blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS). Study No: EFC4582. GlaxoSmithKline Clinical Trial Register2005. BauerKA , ErikssonBI , LassenMR , TurpieAGG . No episode of thrombocytopenia after four‐week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA‐PLUS study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):P2050. DobeshPP . Novel concepts: emerging data and the role of extended prophylaxis following hip fracture surgery. American Journal of Health‐System Pharmacy2003;60(22 Suppl 7):S15‐9. ErikssonBI . A multicenter, randomized, placebo‐controlled, double‐blind study of fondaparinux for the prolonged prevention of venous thromboembolism in hip fracture surgery. Abstracts of the Sicot/Sirot XXII World Congress2002:318. ErikssonBI , LassenMR . Consistency of efficacy of extended thromboprophylaxis with fondaparinux (arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA‐PLUS study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract P2064. ErikssonBI , LassenMR . Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo‐controlled, double‐blind study. Archives of Internal Medicine 2003 Jun 9;163(11):1337‐42. ErikssonBI , LassenMR , ColwellCW , Jr . Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients. Journal of Arthroplasty2004;19(7 Suppl 2):78‐81. LassenM , BauerKA , ErikssonBI , TurpieAGG . Absence of transaminase increase after 4‐week administration of fondaparinux (Arixtra®) a new synthetic and selective inhibitor of factor Xa in the PENTHIFRA‐PLUS study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract number: P2052. ">PENTHIFRA PLUS Study</a>; <a href="./references#CD004179-bbs2-0023" title="BergqvistD , BenoniG , BjorgellO , FredinH , HedlundhU , NicolasS , et al. Low‐molecular‐weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. New England Journal of Medicine1996;335(10):696‐700. BergqvistD , JönssonB . Cost‐effectiveness of prolonged out‐of‐hospital prophylaxis with low‐molecular‐weight heparin following total hip replacement. Haemostasis2000;30 Suppl 2:130‐5. NilssonPE , BergqvistD , BenoniG , BjorgellO , FredinH , HedlundU , et al. The post‐discharge prophylactic management of the orthopedic patient with low‐molecular‐weight heparin: enoxaparin. Orthopedics1997;20 Suppl:22‐5. ">Swedish Study</a>). Six studies had extended duration, but did not meet the five week minimum requirement (<a href="./references#CD004179-bbs2-0017" title="CompPC , SpiroTE , FriedmanRJ , WhitsettTL , JohnsonGJ , GardinerGA , et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. Journal of Bone &amp; Joint Surgery ‐ American Volume2001;83‐A(3):336‐45. SpiroTE . A double‐blind multicenter clinical trial comparing long term enoxaparin and placebo treatments in the prevention of venous thromboembolic disease after hip and knee replacement surgery. Blood. 1997; Vol. 90, issue Suppl 1:295a. ">Comp 2001</a>; <a href="./references#CD004179-bbs2-0018" title="NCT01720108 . Extended venous thromboembolism prophylaxis comparing rivaroxaban to aspirin following total hip and knee arthroplasty (EPCAT II). https://clinicaltrials.gov/ct2/show/NCT01720108 (accessed 30 August 2015). ">EPCAT II</a>; <a href="./references#CD004179-bbs2-0020" title="ManganelliD , PazzagliM , MazzantiniD , PunziG , MancaM , VignaliC , et al. Prolonged prophylaxis with unfractioned heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. Respiration1998;65(5):369‐74. PallaA , ManganelliD , RossiG . Prolonged prophylaxis with unfractioned heparin (UH) is effective to reduce delayed deep vein thrombosis (DVT) in total hip replacement (THR). European Respiratory Journal. 1997; Vol. 10, issue Suppl 25:5S. ">Manganelli 1998</a>; <a href="./references#CD004179-bbs2-0021" title="HaentjensP , DelinceP , The Belgian Nadroparin Post‐Hospital Discharge In Orthopedics (NPHDO) Study Group. Prevention of venous thromboembolism after hospital discharge. Continued pharmacologic prophylaxis versus no prophylaxis in patients undergoing total hip replacement. Hip International2001;11(1):25‐36. HaentjensP , The Belgian Nadroparin Post‐Hospital Discharge in Orthopedics (NPHDO) Study Group. Post‐hospital discharge prevention of deep vein thrombosis with nadroparin calcium after elective total hip replacement. British Journal of Anaesthesia1999;82(Suppl 1):78. The Belgian Nadroparin Post Hospital Discharge in Orthopedics (NPHDO) Study Group. Post hospital discharge prevention of deep vein thrombosis with nadroparin calcium after total hip arthroplasty. Haemostasis. 1998; Vol. 28, issue Suppl 2:292. ">NPHDO Study Group</a>; <a href="./references#CD004179-bbs2-0022" title="Anon . A multicenter, multinational, randomized, double‐blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of VTE in hip fracture surgery. (PENTIHFRA PLUS). Study No: EFC4582. GlaxoSmithKline Clinical Trial Register2005. BauerKA , ErikssonBI , LassenMR , TurpieAGG . No episode of thrombocytopenia after four‐week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA‐PLUS study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):P2050. DobeshPP . Novel concepts: emerging data and the role of extended prophylaxis following hip fracture surgery. American Journal of Health‐System Pharmacy2003;60(22 Suppl 7):S15‐9. ErikssonBI . A multicenter, randomized, placebo‐controlled, double‐blind study of fondaparinux for the prolonged prevention of venous thromboembolism in hip fracture surgery. Abstracts of the Sicot/Sirot XXII World Congress2002:318. ErikssonBI , LassenMR . Consistency of efficacy of extended thromboprophylaxis with fondaparinux (arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA‐PLUS study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract P2064. ErikssonBI , LassenMR . Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo‐controlled, double‐blind study. Archives of Internal Medicine 2003 Jun 9;163(11):1337‐42. ErikssonBI , LassenMR , ColwellCW , Jr . Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients. Journal of Arthroplasty2004;19(7 Suppl 2):78‐81. LassenM , BauerKA , ErikssonBI , TurpieAGG . Absence of transaminase increase after 4‐week administration of fondaparinux (Arixtra®) a new synthetic and selective inhibitor of factor Xa in the PENTHIFRA‐PLUS study. Journal of Thrombosis and Haemostasis2003;1(Suppl 1):Abstract number: P2052. ">PENTHIFRA PLUS Study</a>; <a href="./references#CD004179-bbs2-0023" title="BergqvistD , BenoniG , BjorgellO , FredinH , HedlundhU , NicolasS , et al. Low‐molecular‐weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. New England Journal of Medicine1996;335(10):696‐700. BergqvistD , JönssonB . Cost‐effectiveness of prolonged out‐of‐hospital prophylaxis with low‐molecular‐weight heparin following total hip replacement. Haemostasis2000;30 Suppl 2:130‐5. NilssonPE , BergqvistD , BenoniG , BjorgellO , FredinH , HedlundU , et al. The post‐discharge prophylactic management of the orthopedic patient with low‐molecular‐weight heparin: enoxaparin. Orthopedics1997;20 Suppl:22‐5. ">Swedish Study</a>). <a href="./references#CD004179-bbs2-0019" title="KristensenSS , PedersenP , PedersenNW , SchmidtSA , Kjaersgaard‐AndersenP . Combined treatment with indomethacin and low‐dose heparin after total hip replacement. Journal of Bone and Joint Surgery. American Volume1990;72:447‐9. ">Kristensen 1990</a> did not evaluate a treatment comparison within the scope of this review: heparin plus indomethacin versus heparin plus placebo. </p> <p>A total of 175 records were deemed not relevant mainly due to the duration of the thromboprophylaxis being 10 to 14 days and not extended duration. </p> </section> </section> <section id="CD004179-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD004179-fig-0002">Figure 2</a> and <a href="#CD004179-fig-0003">Figure 3</a> for further information on risk of bias. </p> <div class="figure" id="CD004179-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004179-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD004179-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004179-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Overall risk of bias was moderate to low with the largest concerns being some studies either not reporting on listed outcomes or reporting outcomes they did not pre‐define, leading to selective reporting bias, and other bias, mainly stemming from early termination or potential conflicts of interest due to the involvement of pharmaceutical companies. </p> <section id="CD004179-sec-0071"> <h4 class="title">Allocation</h4> <p>Adequate random sequence generation was described in the majority of studies, but two studies did not provide enough detail to make an assessment, and were rated as unclear (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>). </p> <p>Likewise, nearly all studies provided enough information to determine if allocation concealment was adequate, yet four studies did not give enough detail (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>). </p> </section> <section id="CD004179-sec-0072"> <h4 class="title">Blinding</h4> <p>Performance bias was generally low as most studies were double‐blind and utilised a placebo. However, four studies were given an unclear rating as one study was open‐label (<a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a>) and three studies did not state either way if they were open‐label or double‐blind, but as no placebo was acknowledged, they were most likely open‐label (<a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>; <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>). It is unclear if knowing the treatment would have an effect on the outcomes. </p> <p>All studies, except for two (<a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>) used a blinded assessor or committee to evaluate at least some, if not all, outcomes. <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a> and <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> may have used blinded assessors, but no details were given. </p> </section> <section id="CD004179-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>Twelve of the 16 included studies had low risk of attrition bias as all participants were accounted for in the analysis, and thorough explanations were given for exclusions. Four studies, while all participants were accounted for, did not give adequate explanations for why some participants stopped taking their medication or never started (<a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>). </p> </section> <section id="CD004179-sec-0074"> <h4 class="title">Selective reporting</h4> <p>The majority of studies had no evidence of reporting bias, but two were rated as high risk of bias because one study had bleeding events listed as an outcome but did not fully report the number of events (<a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a>) and the other reported on several outcomes that were not listed as a pre‐planned outcome (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>). The <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a> was given an unclear rating as defined outcomes were not reported on after early termination of the trial. </p> </section> <section id="CD004179-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies were given a high risk of other bias as one study was terminated early due to safety issues and also the funding pharmaceutical company was highly involved in the study design, data collection and analysis (<a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>), and the other study was also terminated early because they had a very high statistical significance with the first 360 enrolled participants (<a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>). A further four studies also had pharmaceutical companies as funding bodies that were very involved in the design, data collection and analysis of the studies, which could be a conflict of interest (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>). </p> </section> </section> <section id="CD004179-sec-0076"> <h3 class="title" id="CD004179-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD004179-tbl-0001"><b>Summary of findings for the main comparison</b> Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</a>; <a href="./full#CD004179-tbl-0002"><b>Summary of findings 2</b> Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</a>; <a href="./full#CD004179-tbl-0003"><b>Summary of findings 3</b> DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</a>; <a href="./full#CD004179-tbl-0004"><b>Summary of findings 4</b> Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</a>; <a href="./full#CD004179-tbl-0005"><b>Summary of findings 5</b> Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</a>; <a href="./full#CD004179-tbl-0006"><b>Summary of findings 6</b> DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</a> </p> <section id="CD004179-sec-0077"> <h4 class="title">Heparin versus placebo</h4> <p>See <a href="./full#CD004179-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./appendices#CD004179-sec-0175">Appendix 2</a> </p> <section id="CD004179-sec-0078"> <h5 class="title">Symptomatic VTE (DVT and PE)</h5> <p>Five studies assessed symptomatic VTE (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>) and the fixed‐effect model found no difference between the study arms: OR 0.59, 95% CI 0.35 to 1.01; participants = 2329; studies = 5; I<sup>2</sup> = 0%; high quality evidence; <a href="./references#CD004179-fig-0004" title="">Analysis 1.1</a>. </p> <p>Subgroup analysis by hip or knee replacement showed no differences between the subgroups and no differences between heparin and placebo were observed for the individual surgery groups (<a href="./references#CD004179-fig-0004" title="">Analysis 1.1</a>). </p> <p>The findings did not change in studies with an in‐hospital or initial phase of 10 to 14 days, or with less than 10 days of in‐hospital/initial phase or when the studies that did not have mandatory, objective detection of DVT at hospital discharge were excluded (data analyses not shown). </p> </section> <section id="CD004179-sec-0079"> <h5 class="title">Symptomatic DVT</h5> <p>Four studies assessed symptomatic DVT (distal or proximal) (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>) and the fixed‐effect model found no difference between the study arms: OR 0.73, 95% CI 0.39 to 1.38; participants = 2019; studies = 4; I<sup>2</sup> = 0%; moderate quality evidence; <a href="./references#CD004179-fig-0005" title="">Analysis 1.2</a>. </p> <p>Subgroup analysis by hip or knee replacement showed no differences between the subgroups and no differences between heparin and placebo were observed for the individual surgery groups (<a href="./references#CD004179-fig-0005" title="">Analysis 1.2</a>). </p> <p>The findings did not change in studies with an in‐hospital or initial phase of 10 to 14 days, or with less than 10 days of in‐hospital/initial phase or when the studies that did not have mandatory, objective detection of DVT at hospital discharge were excluded (data analyses not shown). </p> </section> <section id="CD004179-sec-0080"> <h5 class="title">Symptomatic PE</h5> <p>The fixed‐effect model evaluating three studies for symptomatic PE (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>), showed no difference between heparin or placebo (OR 0.61, 95% CI 0.16 to 2.33; participants = 1595; studies = 3; I<sup>2</sup> = 49%; low quality evidence) <a href="./references#CD004179-fig-0006" title="">Analysis 1.3</a>. </p> <p>Subgroup analysis by hip or knee replacement showed no differences between the subgroups and no differences between heparin and placebo were observed for the individual surgery groups (<a href="./references#CD004179-fig-0006" title="">Analysis 1.3</a>). </p> <p>The findings did not change in studies with an in‐hospital or initial phase of 10 to 14 days, or with less than 10 days of in‐hospital/initial phase or when the studies that did not have mandatory, objective detection of DVT at hospital discharge were excluded (data analyses not shown). </p> <p>Regarding sensitivity analysis, <a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a> was found to account for 64.1% of the participants within this outcome, but after its removal no difference was seen in the findings. </p> </section> <section id="CD004179-sec-0081"> <h5 class="title">Total VTE (symptomatic or asymptomatic)</h5> <p>For the six reporting studies (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>), the fixed‐effect model found decreased odds of any VTE event in favour of heparin (OR 0.39, 95% CI 0.28 to 0.56; participants = 2544; studies = 6; I<sup>2</sup> = 0%; high quality evidence) <a href="./references#CD004179-fig-0007" title="">Analysis 1.4</a>. </p> <p>For the five studies reporting on hip replacement, the fixed‐effect model found decreased odds in favour of heparin (OR 0.37, 95% CI 0.25 to 0.56; participants = 1511; studies = 5; I<sup>2</sup> = 0%) <a href="./references#CD004179-fig-0007" title="">Analysis 1.4</a>. The single study reporting on knee replacement found no difference between the study arms (OR 0.78, 95% CI 0.21 to 2.92; participants = 723) <a href="./references#CD004179-fig-0007" title="">Analysis 1.4</a>. The single study reporting on a combined group of hip or knee replacement participants found decreased odds in favour of heparin (OR 0.38, 95% CI 0.16 to 0.90; participants = 310) <a href="./references#CD004179-fig-0007" title="">Analysis 1.4</a>. </p> <p>When comparing the subgroup of studies evaluating 10 to 14 day in‐hospital/initial phase treatment duration and those that included objective DVT screening at discharge, the findings were still in favour of heparin treatment (data analyses not shown). </p> </section> <section id="CD004179-sec-0082"> <h5 class="title">Asymptomatic DVT</h5> <p>In the five studies that reported on asymptomatic DVT (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>), the fixed‐effect model showed a decreased odds favouring the heparin treatment group (OR 0.38, 95% CI 0.24 to 0.60; participants = 1304; studies = 5; I<sup>2</sup> = 0%; high quality evidence) <a href="./references#CD004179-fig-0008" title="">Analysis 1.5</a>. </p> <p>When evaluating hip replacement only, the four included studies retained a decreased odds of asymptomatic DVT (OR 0.35, 95% CI 0.21 to 0.58; participants = 994; studies = 4; I<sup>2</sup> = 0%) <a href="./references#CD004179-fig-0008" title="">Analysis 1.5</a>. The single study reporting on a combined group of hip or knee replacement participants found no difference between the study arms (OR 0.54, 95% CI 0.19 to 1.52; participants = 310) <a href="./references#CD004179-fig-0008" title="">Analysis 1.5</a>. </p> <p>When comparing the subgroup of studies evaluating 10 to 14 day in‐hospital/initial phase treatment duration and those that included objective DVT screening at discharge, the findings were still in favour of heparin treatment (data analyses not shown). </p> </section> <section id="CD004179-sec-0083"> <h5 class="title">Asymptomatic proximal DVT</h5> <p>None of the included studies reported on asymptomatic proximal DVT. Many did report asymptomatic or proximal DVT separately, but given the provided data, it was not possible to determine which events fell into both categories. </p> </section> <section id="CD004179-sec-0084"> <h5 class="title">Asymptomatic distal DVT</h5> <p>No studies reported asymptomatic distal DVT. See above description. Many did report asymptomatic or distal DVT separately, but given the provided data, it was not possible to determine which events fell into both categories. </p> </section> <section id="CD004179-sec-0085"> <h5 class="title">All‐cause mortality</h5> <p>For the five included studies that evaluated all‐cause mortality for heparin versus placebo (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>), there was no difference between the study arms (OR 1.01, 95% CI 0.31 to 3.26; participants = 2518; studies = 5; I<sup>2</sup> = 0%; moderate quality evidence) <a href="./references#CD004179-fig-0009" title="">Analysis 1.6</a>. </p> <p>There was also no difference in the four studies evaluating participants undergoing hip replacement (OR 0.56, 95% CI 0.11 to 2.75; participants = 1485; studies = 4; I<sup>2</sup> = 0%) <a href="./references#CD004179-fig-0009" title="">Analysis 1.6</a>, or in the one study undergoing knee replacement (OR 0.98, 95% CI 0.06 to 15.65; participants = 723) <a href="./references#CD004179-fig-0009" title="">Analysis 1.6</a>. The single study reporting on a combined group of hip or knee replacement participants also found no difference between the study arms (OR 4.69, 95% CI 0.22 to 98.42; participants = 310) <a href="./references#CD004179-fig-0009" title="">Analysis 1.6</a>. </p> <p>When only evaluating studies that had an in‐hospital/initial phase of 10 to 14 days or studies that included objective DVT verification at discharge, there was still no difference between study arms (data analysis not shown). </p> </section> <section id="CD004179-sec-0086"> <h5 class="title">Adverse events</h5> <p>Only two studies evaluating participants undergoing hip replacement reported on adverse events (<a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>) and found no difference between study arms (OR 1.06, 95% CI 0.68 to 1.64; participants = 460; I<sup>2</sup> = 4%; moderate quality evidence <a href="./references#CD004179-fig-0010" title="">Analysis 1.7</a>), although it should be noted that there was minimal or no description of the criteria for adverse event reporting, and it varied greatly between the two reporting studies. </p> <p>Too few studies remained for subgroup analysis by initial phase duration or objective DVT verification at discharge (data analyses not shown). </p> </section> <section id="CD004179-sec-0087"> <h5 class="title">Bleeding events (major, clinically relevant non‐major, minor)</h5> <p>Major bleeding was reported in five studies (<a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>) and minor bleeding was reported in five studies (<a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>). Clinically relevant non‐major bleeding was not reported by the included studies comparing heparin and placebo. </p> <p>There was no difference in major bleeding between the study arms (OR 0.59, 95% CI 0.14 to 2.46; participants = 2500; studies = 5; I<sup>2</sup> = 0%; moderate quality evidence <a href="./references#CD004179-fig-0011" title="">Analysis 1.8</a>. </p> <p>For participants undergoing hip replacement, there was no difference in major bleeding (OR 0.32, 95% CI 0.03 to 3.10; participants = 1494; studies = 4; I<sup>2</sup> = 0% <a href="./references#CD004179-fig-0011" title="">Analysis 1.8</a>. There was no difference in major bleeding in participants undergoing knee replacement (OR 0.99, 95% CI 0.14 to 7.06; participants = 696; studies = 1; I<sup>2</sup> = 0% <a href="./references#CD004179-fig-0011" title="">Analysis 1.8</a>). The single study reporting on a combined group of hip or knee replacement participants reported no major bleeding in either study arm (0/161 heparin versus 0/149 placebo). </p> <p>There was an increased odds of minor bleeding in the heparin treatment group compared with placebo (OR 2.01, 95% CI 1.43 to 2.81; participants = 2500; studies = 5; I<sup>2</sup> = 0%; high quality evidence) <a href="./references#CD004179-fig-0012" title="">Analysis 1.9</a>. </p> <p>For participants undergoing hip replacement, there was an increased odds of minor bleeding in the heparin treatment group compared with placebo (OR 2.25, 95% CI 1.53 to 3.30; participants = 1494; studies = 4; I<sup>2</sup> = 0%) <a href="./references#CD004179-fig-0012" title="">Analysis 1.9</a>. There was no difference in minor bleeding in participants undergoing knee replacement (OR 1.23, 95% CI 0.58 to 2.59; participants = 696; studies = 1 <a href="./references#CD004179-fig-0012" title="">Analysis 1.9</a>). The single study reporting on a combined group of hip and knee replacement participants also reported no difference in minor bleeding in both study arms (OR 2.79, 95% CI 0.11 to 69.13; participants = 310; studies = 1; I<sup>2</sup> = 0%) <a href="./references#CD004179-fig-0012" title="">Analysis 1.9</a>. </p> <p>There were no changes to the findings when only comparing studies with a in‐hospital/initial phase of 10 to 14 days or studies that had objective DVT testing at discharge (data analyses not shown). </p> </section> <section id="CD004179-sec-0088"> <h5 class="title">Reoperation</h5> <p>The <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a> reported that two participants required reoperation but did not report from which study arm. <a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a> reported reoperation due to bleeding to be a safety outcome but did not present data. The <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>, <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a> and <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a> did not report on reoperation. The <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a> reported that no reoperations were required following bleeding <a href="./references#CD004179-fig-0013" title="">Analysis 1.10</a>. </p> </section> <section id="CD004179-sec-0089"> <h5 class="title">Wound infection</h5> <p><a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>, <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>, <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a> and <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a> did not report on wound infection. <a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a> reported that the majority of adverse events were luxation of prosthesis and infection but did not report specific numbers for the study arms. The <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a> reported wound infection as part of complications associated with wound haematoma but no specific details for infection were provided. </p> </section> <section id="CD004179-sec-0090"> <h5 class="title">Wound healing</h5> <p>None of the six studies comparing heparin with placebo reported wound healing (<a href="./references#CD004179-bbs2-0003" title="Anon . Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. Prescrire International2000;9(45):197‐98. ArnesenH , DahlOE , AspelinT , SeljeflotI , KierulfP , LybergT . Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. Journal of Thrombosis and Haemostasis2003;1(5):971‐5. DahlOE , AndreassenG , AspelinT , MullerC , MathiesenP , NyhusS , et al. Prolonged thromboprophylaxis following hip replacement surgery‐‐results of a double‐blind, prospective, randomised, placebo‐controlled study with dalteparin (Fragmin). Thrombosis and Haemostasis1997;77(1):26‐31. DahlOE , AndreassenG , MullerC , MathisenP , NyhusS , AspelinT , et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip replacement surgery (HRS). Thrombosis and Haemostasis1995;73(6):1094‐Abstract No 743. ">Dahl 1997</a>; <a href="./references#CD004179-bbs2-0004" title="LassenMR , BorrisLC . Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty ‐ a placebo controlled study. Thrombosis and Haemostasis. 1995; Vol. 73, issue 6:1104. LassenMR , BorrisLC , AndersonBS , JensenHP , Skejo BroHP , AndersenG , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty‐‐the Danish Prolonged Prophylaxis (DaPP) Study. Thrombosis Research1998;89(6):281‐7. ">DaPP Study</a>; <a href="./references#CD004179-bbs2-0006" title="HullRD . New insights into extended prophylaxis after orthopaedic surgery ‐ the North American Fragmin Trial experience. Haemostasis. 2000; Vol. 30, issue Suppl 2:95‐100. HullRD , PineoGF , FrancisC , Bergqvist , D , FelleniusC , SoderbergK , et al. Low‐molecular‐weight heparin prophylaxis using dalteparin extended out‐of‐hospital vs in‐hospital warfarin/out‐of‐hospital placebo in hip arthroplasty patients: a double‐blind, randomized comparison. North American Fragmin Trial Investigators. Archives of Internal Medicine2000;160(14):2208‐15. ">Fragmin Trial</a>; <a href="./references#CD004179-bbs2-0007" title="PlanesA , VochelleN . The post‐hospital discharge venous thrombosis risk of the orthopedic patient. Orthopedics1997;20(2 Suppl):18‐21. PlanesA , VochelleN , CompanD , WeisslingerN , HuetY . Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. Orthopaedic Transactions. 1996; Vol. 20, issue 1:274. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , CompanD , et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double‐blind placebo‐controlled trial. Drugs1996;52(Suppl 7):47‐54. PlanesA , VochelleN , DarmonJ‐Y , FagolaM , BellaudM , HuetY . Risk of deep‐venous thrombosis after hospital discharge in patients having undergone total hip replacement: double‐blind randomised comparison of enoxaparin versus placebo. Lancet1996;348(9022):224‐8. PlanesA , VochelleN , DarmonJY . Out‐of‐hospital prophylaxis with low‐molecular‐weight heparin in hip surgery: the French study‐‐venographic outcome at 35 days. Chest1998;114(2 Suppl Evidence):125S‐9S. ">French Study</a>; <a href="./references#CD004179-bbs2-0008" title="HeitJA , ElliottCG , TrowbridgeAA , HirshJ , GentM . Extended out‐of‐hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. Blood1998;92:500a. HeitJA , ElliottCG , TrowbridgeAA , MorreyBF , GentM , HirshJ . Ardeparin sodium for extended out‐of‐hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double‐blind, placebo‐controlled trial. Annals of Internal Medicine2000;132(11):853‐61. ">Heit 2000</a>; <a href="./references#CD004179-bbs2-0009" title="KolbG , BodamerI , GalsterH , GrambachK , KoudelaK , EiseleRR , et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. Journal of Thrombosis and Haemostasis. 2003; Vol. Suppl:Abstract: P1868. KolbG , BodamerI , GalsterH , SeidlmayerC , GrambachK , KoudelaK , et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thrombosis and Haemostasis2003;90(6):1100‐5. ">Kolb 2003</a>). </p> </section> </section> <section id="CD004179-sec-0091"> <h4 class="title">Vitamin K antagonists versus placebo</h4> <p>One study evaluated vitamin K antagonist versus placebo (<a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a>), in participants undergoing hip replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. We found no difference between the treatment groups for any of the evaluated outcomes except for total VTE. See <a href="./full#CD004179-tbl-0002">summary of findings Table 2</a> and <a href="./appendices#CD004179-sec-0176">Appendix 3</a>. </p> <section id="CD004179-sec-0092"> <h5 class="title">Symptomatic VTE (DVT and PE)</h5> <p>No difference between VKA and placebo was observed for symptomatic VTE (OR 0.10, 95% CI 0.01 to 1.94; participants = 360; moderate quality evidence) <a href="./references#CD004179-fig-0014" title="">Analysis 2.1</a>. </p> </section> <section id="CD004179-sec-0093"> <h5 class="title">Symptomatic DVT</h5> <p>No difference between VKA and placebo was observed for symptomatic DVT (OR 0.13, 95% CI 0.01 to 2.62; participants = 360; moderate quality evidence) <a href="./references#CD004179-fig-0015" title="">Analysis 2.2</a>. </p> </section> <section id="CD004179-sec-0094"> <h5 class="title">Symptomatic PE</h5> <p>No difference between VKA and placebo was observed for symptomatic PE (OR 0.32, 95% CI 0.01 to 7.84; participants = 360; moderate quality evidence) <a href="./references#CD004179-fig-0016" title="">Analysis 2.3</a>. </p> </section> <section id="CD004179-sec-0095"> <h5 class="title">Total VTE (symptomatic or asymptomatic)</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> showed decreased odds of any VTE event in favour of VKA versus placebo (OR 0.10, 95% CI 0.01 to 0.81; participants = 360; moderate quality evidence) <a href="./references#CD004179-fig-0017" title="">Analysis 2.4</a>. </p> </section> <section id="CD004179-sec-0096"> <h5 class="title">Asymptomatic DVT</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> did not report on asymptomatic DVT. </p> </section> <section id="CD004179-sec-0097"> <h5 class="title">Asymptomatic proximal DVT</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> did not report on asymptomatic proximal DVT. </p> </section> <section id="CD004179-sec-0098"> <h5 class="title">Asymptomatic distal DVT</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> did not report on asymptomatic distal DVT. </p> </section> <section id="CD004179-sec-0099"> <h5 class="title">All‐cause mortality</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> reported no deaths in either study arm (0/184 VKA versus 0/176 placebo) <a href="./references#CD004179-fig-0018" title="">Analysis 2.5</a>. </p> </section> <section id="CD004179-sec-0100"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> reported no adverse events in either study arm (0/184 VKA versus 0/176 placebo) <a href="./references#CD004179-fig-0019" title="">Analysis 2.6</a>. </p> </section> <section id="CD004179-sec-0101"> <h5 class="title">Bleeding events (major, clinically relevant non‐major, minor)</h5> <p>There were no differences between the study arms in major bleeding (OR 2.89, 95% CI 0.12 to 71.31; participants = 360; low quality evidence) <a href="./references#CD004179-fig-0020" title="">Analysis 2.7</a>. <a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> did not report clinically relevant non‐major bleeding or minor bleeding. </p> </section> <section id="CD004179-sec-0102"> <h5 class="title">Reoperation</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> did not report on reoperation. </p> </section> <section id="CD004179-sec-0103"> <h5 class="title">Wound infection</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> did not report on wound infection </p> </section> <section id="CD004179-sec-0104"> <h5 class="title">Wound healing</h5> <p><a href="./references#CD004179-bbs2-0010" title="PrandoniP , BruchiO , SabbionP , TanduoC , ScudellerA , SardellaC , et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Archives of Internal Medicine2002;162(17):1966‐71. ">Prandoni 2002</a> did not report on wound healing. </p> </section> </section> <section id="CD004179-sec-0105"> <h4 class="title">DOACs versus placebo</h4> <p>Two studies evaluated DOACs versus placebo (<a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a>) in participants undergoing hip replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> reported assessment of symptomatic DVT only and is therefore only included in the analysis for symptomatic DVT. See <a href="./full#CD004179-tbl-0003">summary of findings Table 3</a> and <a href="./appendices#CD004179-sec-0177">Appendix 4</a>. </p> <section id="CD004179-sec-0106"> <h5 class="title">Symptomatic VTE (DVT and PE)</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> reported on symptomatic VTE showing a reduced odds of VTE in favour of the DOAC treatment (OR 0.20, 95% CI 0.06 to 0.68; participants = 2419; moderate quality evidence) <a href="./references#CD004179-fig-0021" title="">Analysis 3.1</a>. </p> </section> <section id="CD004179-sec-0107"> <h5 class="title">Symptomatic DVT</h5> <p>A reduced odds of symptomatic DVT in favour of DOAC treatment was observed (OR 0.18, 95% CI 0.04 to 0.81; participants = 2459; studies = 2; I<sup>2</sup> = not applicable; high quality evidence) <a href="./references#CD004179-fig-0022" title="">Analysis 3.2</a> </p> </section> <section id="CD004179-sec-0108"> <h5 class="title">Symptomatic PE</h5> <p>No difference between DOACs and placebo was observed for symptomatic PE (OR 0.25, 95% CI 0.03 to 2.25; participants = 1733; studies = 1; low quality evidence) <a href="./references#CD004179-fig-0023" title="">Analysis 3.3</a>. </p> </section> <section id="CD004179-sec-0109"> <h5 class="title">Total VTE (symptomatic or asymptomatic)</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> showed decreased odds of any VTE event in favour of DOAC treatment versus placebo (OR 0.19, 95% CI 0.11 to 0.33; moderate quality evidence) <a href="./references#CD004179-fig-0024" title="">Analysis 3.4</a>. </p> </section> <section id="CD004179-sec-0110"> <h5 class="title">Asymptomatic DVT</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> and <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> do not report on asymptomatic DVT. </p> </section> <section id="CD004179-sec-0111"> <h5 class="title">Asymptomatic proximal DVT</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> and <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> do not report on asymptomatic proximal DVT. </p> </section> <section id="CD004179-sec-0112"> <h5 class="title">Asymptomatic distal DVT</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> and <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> do not report on asymptomatic distal DVT. </p> </section> <section id="CD004179-sec-0113"> <h5 class="title">All‐cause mortality</h5> <p>There were no differences between the study arms in all‐cause mortality (OR 0.33, 95% CI 0.07 to 1.66; participants = 1733; studies = 1; low quality evidence <a href="./references#CD004179-fig-0025" title="">Analysis 3.5</a>. </p> </section> <section id="CD004179-sec-0114"> <h5 class="title">Adverse events</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> reported no differences in adverse events (OR 0.87, 95% CI 0.74 to 1.03; participants = 2457; moderate quality evidence) <a href="./references#CD004179-fig-0026" title="">Analysis 3.6</a>. </p> </section> <section id="CD004179-sec-0115"> <h5 class="title">Bleeding events (major, clinically relevant non‐major, minor)</h5> <p>There were no differences in any of the bleeding event categories reported by <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a>; major bleeding (OR 1.00, 95% CI 0.06 to 16.02; participants = 2457; low quality evidence <a href="./references#CD004179-fig-0027" title="">Analysis 3.7</a>); clinically relevant bleeding (OR 1.22, 95% CI 0.76 to 1.95; participants = 2457; moderate quality evidence <a href="./references#CD004179-fig-0028" title="">Analysis 3.8</a>); minor bleeding (OR 1.18, 95% CI 0.74 to 1.88; participants = 2457; moderate quality evidence <a href="./references#CD004179-fig-0029" title="">Analysis 3.9</a>. </p> </section> <section id="CD004179-sec-0116"> <h5 class="title">Reoperation</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> reported reoperation following bleeding; no cases of reoperation (0/1228 DOAC versus 0/1229 placebo) were reported <a href="./references#CD004179-fig-0030" title="">Analysis 3.10</a>. </p> </section> <section id="CD004179-sec-0117"> <h5 class="title">Wound infection</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> reported no differences in post‐operative wound infections (OR 1.34, 95% CI 0.46 to 3.86; participants = 2457; low quality evidence) <a href="./references#CD004179-fig-0031" title="">Analysis 3.11</a>. </p> </section> <section id="CD004179-sec-0118"> <h5 class="title">Wound healing</h5> <p>The <a href="./references#CD004179-bbs2-0012" title="KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , BandelTJ , et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short‐term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended duration rivaroxaban versus short‐term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double‐blind, randomised controlled trial. Lancet2008;372(9632):31‐9. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. Extended thromboprophylaxis with rivaroxaban compared with short‐term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):307. KakkarAK , BrennerB , DahlOE , ErikssonBI , MouretP , MuntzJ , et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short‐term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). British Journal of Haematology2008;141(Suppl 1):65. MouretP , KakkarAK , BrennerB , DahlOE , ErikssonBI , MuntzJ , et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short‐term thrombosis prophylaxis with enoxaparin after total hip replacement: The RECORD2 study. Medizinische Klinik2008;103(3):15. NCT00332020 . Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double‐blind, randomized study of BAY 59‐7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&amp;rank=1 (accessed 30 August 2015). ">RECORD 2 Trial</a> and <a href="./references#CD004179-bbs2-0016" title="ZhangH , LinJ , LiH , GuanZ , ZhouD , KonB , et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. National Medical Journal of China2014;94(7):525‐8. ">Zhang 2014</a> did not report wound healing. </p> </section> </section> <section id="CD004179-sec-0119"> <h4 class="title">Anticoagulant treatments chosen at the investigators' discretion versus placebo</h4> <p>One study evaluated anticoagulant treatment chosen at the investigators' discretion versus placebo (<a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a>) in participants undergoing knee replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. The anticoagulation treatment was either heparin, enoxaparin, dalteparin, tinzaparin, nadroparin or fondaparinux, at the discretion of the investigator at the study location. See <a href="./full#CD004179-tbl-0004">summary of findings Table 4</a> and <a href="./appendices#CD004179-sec-0178">Appendix 5</a>. </p> <section id="CD004179-sec-0120"> <h5 class="title">Symptomatic VTE (DVT and PE)</h5> <p>No difference between anticoagulant treatment and placebo was observed for symptomatic VTE (OR 0.50, 95% CI 0.09 to 2.74; participants = 557; low quality evidence) <a href="./references#CD004179-fig-0032" title="">Analysis 4.1</a>. </p> </section> <section id="CD004179-sec-0121"> <h5 class="title">Symptomatic DVT</h5> <p>No difference between anticoagulant treatment and placebo was observed for symptomatic DVT (OR 0.33, 95% CI 0.03 to 3.21; participants = 557; low quality evidence) <a href="./references#CD004179-fig-0033" title="">Analysis 4.2</a>. </p> </section> <section id="CD004179-sec-0122"> <h5 class="title">Symptomatic PE</h5> <p>No difference between anticoagulant treatment and placebo was observed for symptomatic PE (OR 1.00, 95% CI 0.06 to 16.13; participants = 557; low quality evidence) <a href="./references#CD004179-fig-0034" title="">Analysis 4.3</a>. </p> </section> <section id="CD004179-sec-0123"> <h5 class="title">Total VTE (symptomatic or asymptomatic)</h5> <p>The <a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> study showed decreased odds of any VTE event in favour of anticoagulant treatment versus placebo (OR 0.26, 95% CI 0.14 to 0.50; participants = 557; moderate quality evidence) <a href="./references#CD004179-fig-0035" title="">Analysis 4.4</a>. </p> </section> <section id="CD004179-sec-0124"> <h5 class="title">Asymptomatic DVT</h5> <p><a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> showed a significant difference in new cases of asymptomatic DVT favouring anticoagulant treatment compared to placebo (OR 0.26, 95% CI 0.13 to 0.54; participants = 557; moderate quality evidence) <a href="./references#CD004179-fig-0036" title="">Analysis 4.5</a>. <a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> reported on asymptomatic distal DVT cases only. </p> </section> <section id="CD004179-sec-0125"> <h5 class="title">Asymptomatic proximal DVT</h5> <p><a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> did not report asymptomatic proximal DVT. </p> </section> <section id="CD004179-sec-0126"> <h5 class="title">Asymptomatic distal DVT</h5> <p><a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> reported asymptomatic distal DVT as described above (<a href="./references#CD004179-fig-0037" title="">Analysis 4.6</a>). </p> </section> <section id="CD004179-sec-0127"> <h5 class="title">All‐cause mortality</h5> <p><a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> reported no deaths in either study arm (0/422 anticoagulant treatment versus 0/420 placebo) <a href="./references#CD004179-fig-0038" title="">Analysis 4.7</a>. </p> </section> <section id="CD004179-sec-0128"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> did not report adverse events. </p> </section> <section id="CD004179-sec-0129"> <h5 class="title">Bleeding events (major, clinically relevant non‐major, minor)</h5> <p>There were no differences between the treatment groups in major bleeding (OR 5.05, 95% CI 0.24 to 105.76; participants = 557; low quality evidence). <a href="./references#CD004179-fig-0039" title="">Analysis 4.8</a>. <a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> did not report clinically relevant non‐major bleeding or minor bleeding. </p> </section> <section id="CD004179-sec-0130"> <h5 class="title">Reoperation</h5> <p><a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> reported on reoperation as part of their definition of major bleeding outcome (bleeding leading to reoperation) but did not report this data separately. </p> </section> <section id="CD004179-sec-0131"> <h5 class="title">Wound infection</h5> <p><a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> did not report on wound infection. </p> </section> <section id="CD004179-sec-0132"> <h5 class="title">Wound healing</h5> <p><a href="./references#CD004179-bbs2-0002" title="BarrellierMT , LebelB , ParientiJJ , MismettiP , DutheilJJ , VielpeauC , et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. Thrombosis Research2010;126(4):e298‐304. ">Barrellier 2010</a> did not report on wound healing. </p> </section> </section> <section id="CD004179-sec-0133"> <h4 class="title">Vitamin K antagonists versus heparin</h4> <p>One study evaluated vitamin K antagonists versus heparin (<a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a>) in participants undergoing hip replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. We found no difference between the treatment groups for any of the evaluated outcomes. See <a href="./full#CD004179-tbl-0005">summary of findings Table 5</a> and <a href="./appendices#CD004179-sec-0179">Appendix 6</a>. </p> <section id="CD004179-sec-0134"> <h5 class="title">Symptomatic VTE (DVT and PE)</h5> <p>No difference was observed in symptomatic VTE between the treatment groups (OR 1.64, 95% CI 0.85 to 3.16; participants = 1279; low quality evidence) <a href="./references#CD004179-fig-0040" title="">Analysis 5.1</a>. </p> </section> <section id="CD004179-sec-0135"> <h5 class="title">Symptomatic DVT</h5> <p>There was also no difference between the treatment groups for symptomatic DVT (OR 1.36, 95% CI 0.69 to 2.68; participants = 1279; low quality evidence) <a href="./references#CD004179-fig-0041" title="">Analysis 5.2</a>. </p> </section> <section id="CD004179-sec-0136"> <h5 class="title">Symptomatic PE</h5> <p>No cases of PE were reported in the heparin group (0/643) compared with 4 cases in the VKA group (4/636) . No difference was found between the treatment groups for the outcome of symptomatic PE (OR 9.16, 95% CI 0.49 to 170.42; participants = 1279; low quality evidence) <a href="./references#CD004179-fig-0042" title="">Analysis 5.3</a>. </p> </section> <section id="CD004179-sec-0137"> <h5 class="title">Total VTE (symptomatic or asymptomatic)</h5> <p>There was no difference in total VTE between the treatment groups (OR 1.64, 95% CI 0.85 to 3.16; participants = 1279; low quality evidence) <a href="./references#CD004179-fig-0043" title="">Analysis 5.4</a> . </p> </section> <section id="CD004179-sec-0138"> <h5 class="title">Asymptomatic DVT</h5> <p>The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> did not report asymptomatic DVT. </p> </section> <section id="CD004179-sec-0139"> <h5 class="title">Asymptomatic proximal DVT</h5> <p>The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> did not report asymptomatic proximal DVT. </p> </section> <section id="CD004179-sec-0140"> <h5 class="title">Asymptomatic distal DVT</h5> <p>The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> did not report asymptomatic distal DVT. </p> </section> <section id="CD004179-sec-0141"> <h5 class="title">All‐cause mortality</h5> <p>No cases of death were reported in the heparin group (0/643) compared with 2 cases in the VKA group (2/636). There was no difference in all‐cause mortality between the treatment groups (OR 5.07, 95% CI 0.24 to 105.83; participants = 1279; low quality evidence) <a href="./references#CD004179-fig-0044" title="">Analysis 5.5</a>. </p> </section> <section id="CD004179-sec-0142"> <h5 class="title">Adverse events</h5> <p>The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> did not report adverse events. </p> </section> <section id="CD004179-sec-0143"> <h5 class="title">Bleeding events (major, clinically relevant non‐major, minor)</h5> <p>There were no differences between the treatment groups in major or minor bleeding (OR 3.87, 95% CI 1.91 to 7.85; participants = 1272; low quality evidence, <a href="./references#CD004179-fig-0045" title="">Analysis 5.6</a>, and OR 1.33, 95% CI 0.64 to 2.76; participants = 1279; low quality evidence <a href="./references#CD004179-fig-0046" title="">Analysis 5.7</a>, respectively). The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> did not report clinically relevant non‐major bleeding. </p> </section> <section id="CD004179-sec-0144"> <h5 class="title">Reoperation</h5> <p>The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> reported on reoperation as part of their definition of major bleeding outcome (bleeding leading to reoperation; reoperation was required in 11 participants (two in the reviparin group and nine in the acecoumarol group (OR 4.60, 95% CI 0.99 to 21.38; participants = 1279; low quality evidence). </p> </section> <section id="CD004179-sec-0145"> <h5 class="title">Wound infection</h5> <p>The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> did not report wound infection. </p> </section> <section id="CD004179-sec-0146"> <h5 class="title">Wound healing</h5> <p>The <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a> did not report wound healing. </p> </section> </section> <section id="CD004179-sec-0147"> <h4 class="title">DOACs versus heparin</h4> <p>Five studies evaluated DOACs versus heparin therapy (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>). The studies evaluating DOACs versus heparin were only performed in participants undergoing hip replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. As these studies compared two different anticoagulant treatments and randomised participants prior to surgery, there was no initial phase and objective assessment of VTE after the initial phase. Therefore these subgroup analyses were not possible. We found no difference between the treatment groups for most of the evaluated outcomes. Due to heterogeneity in the data, some of the meta‐analyses in this treatment profile used random‐effects models. See <a href="./full#CD004179-tbl-0006">summary of findings Table 6</a> and <a href="./appendices#CD004179-sec-0180">Appendix 7</a>. </p> <section id="CD004179-sec-0148"> <h5 class="title">Symptomatic VTE (DVT and PE)</h5> <p>The random‐effects model evaluating five studies (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) found no difference in symptomatic VTE between the treatment groups (OR 0.70, 95% CI 0.28 to 1.70; participants = 15,977; I<sup>2</sup> = 55%; low quality evidence) <a href="./references#CD004179-fig-0048" title="">Analysis 6.1</a>. </p> </section> <section id="CD004179-sec-0149"> <h5 class="title">Symptomatic DVT</h5> <p>There was no difference between the treatment groups for symptomatic DVT, as evaluated by the random‐effects model in five studies (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) (OR 0.60, 95% CI 0.11 to 3.27; participants = 15,977; I<sup>2</sup> = 65%; low quality evidence) <a href="./references#CD004179-fig-0049" title="">Analysis 6.2</a>. </p> </section> <section id="CD004179-sec-0150"> <h5 class="title">Symptomatic PE</h5> <p>No difference was found between the DOAC and LMWH treatment groups for the outcome of symptomatic PE (OR 0.91, 95% CI 0.43 to 1.94; participants = 14,731; studies = 5; I<sup>2</sup> = 0%; moderate quality evidence) <a href="./references#CD004179-fig-0050" title="">Analysis 6.3</a>. </p> </section> <section id="CD004179-sec-0151"> <h5 class="title">Total VTE (symptomatic or asymptomatic)</h5> <p>There was significant difference in total VTE in the random‐effects model evaluating four studies favouring DOACs (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) (OR 0.53, 95% CI 0.29 to 0.97; participants = 12,447; I<sup>2</sup> = 87%; moderate quality evidence) <a href="./references#CD004179-fig-0051" title="">Analysis 6.4</a>. </p> </section> <section id="CD004179-sec-0152"> <h5 class="title">Asymptomatic DVT</h5> <p>In the random‐effects model, there was no difference in asymptomatic DVT between treatment groups in the two reporting studies (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) (OR 0.56, 95% CI 0.19 to 1.59; participants = 6559; I<sup>2</sup> = 92%; low quality evidence) <a href="./references#CD004179-fig-0052" title="">Analysis 6.5</a>. </p> </section> <section id="CD004179-sec-0153"> <h5 class="title">Asymptomatic proximal DVT</h5> <p>Only a single study (<a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) reported on asymptomatic proximal DVT (OR 0.73, 95% CI 0.46 to 1.15; participants = 2704; moderate quality evidence) <a href="./references#CD004179-fig-0053" title="">Analysis 6.6</a>. </p> </section> <section id="CD004179-sec-0154"> <h5 class="title">Asymptomatic distal DVT</h5> <p>As for asymptomatic proximal DVT, a single study (<a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) reported on asymptomatic distal DVT (OR 1.22, 95% CI 0.75 to 1.99; participants = 2639; moderate quality evidence) <a href="./references#CD004179-fig-0054" title="">Analysis 6.7</a>. </p> </section> <section id="CD004179-sec-0155"> <h5 class="title">All‐cause mortality</h5> <p>For the five reporting studies (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>), there was no difference in all‐cause mortality between the treatment groups based on the fixed‐effect model ((OR 1.63, 95% CI 0.64 to 4.16; participants = 14,966; studies = 5; I<sup>2</sup> = 0%; moderate quality evidence) <a href="./references#CD004179-fig-0055" title="">Analysis 6.8</a>. Regarding sensitivity analysis, the <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a> was found to account for 56% of the participants within this outcome, but after its removal no difference was seen in the findings. </p> </section> <section id="CD004179-sec-0156"> <h5 class="title">Adverse events</h5> <p>There was also no difference in adverse events between treatment groups in the three studies reporting adverse events (<a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) (OR 0.96, 95% CI 0.88 to 1.05; participants = 9908; studies = 3; I<sup>2</sup> = 0%; high quality evidence) <a href="./references#CD004179-fig-0056" title="">Analysis 6.9</a>. Regarding sensitivity analysis, the <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a> was found to account for 50.8% of the participants within this outcome, but after its removal no difference was seen in the findings. </p> </section> <section id="CD004179-sec-0157"> <h5 class="title">Bleeding events (major, clinically relevant non‐major, minor)</h5> <p>Major bleeding was reported in five studies (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>), clinically relevant non‐major bleeding was reported in four studies (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>), and minor bleeding was reported in four studies (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>). </p> <p>There were no differences in any of the bleeding event categories within the studies reporting on bleeding events; major bleeding, OR 1.11, 95% CI 0.79 to 1.54; participants = 16,199; studies = 5; I<sup>2</sup> = 21%, high quality evidence <a href="./references#CD004179-fig-0057" title="">Analysis 6.10</a>; clinically relevant bleeding OR 1.08, 95% CI 0.90 to 1.28; participants = 15,241; studies = 4; I<sup>2</sup> = 7%, high quality evidence) <a href="./references#CD004179-fig-0058" title="">Analysis 6.11</a>; minor bleeding OR 0.95, 95% CI 0.82 to 1.10; participants = 11,766; studies = 4; I<sup>2</sup> = 0%, high quality evidence <a href="./references#CD004179-fig-0059" title="">Analysis 6.12</a>. </p> <p>For minor bleeding, <a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a> accounted for 53.3% of the participants, and when removed in a sensitivity analysis there were no differences in the association. </p> </section> <section id="CD004179-sec-0158"> <h5 class="title">Reoperation</h5> <p>Four studies reported on reoperation relating to bleeding (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>) showing no differences between the study arms (OR 1.06, 95% CI 0.34 to 3.24; participants = 15241; studies = 4; I<sup>2</sup> = 0%; moderate quality evidence) <a href="./references#CD004179-fig-0060" title="">Analysis 6.13</a>. </p> <p>The <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a> accounted for &gt; 50 % of the weight and when removed in a sensitivity analysis there were no differences in the association. </p> </section> <section id="CD004179-sec-0159"> <h5 class="title">Wound infection</h5> <p>Three studies reported on wound infection (<a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>). The <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a> reported one participant who died of septicaemia and GI bleeding following ischaemic bowel resection but reported no other cases of wound infection. Pooling <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a> and <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a> showed no differences in wound infections between the treatment arms (OR 0.89, 95% CI 0.46 to 1.72; participants = 6446; studies = 2; I<sup>2</sup> = 0%; moderate quality evidence) <a href="./references#CD004179-fig-0061" title="">Analysis 6.14</a>. </p> </section> <section id="CD004179-sec-0160"> <h5 class="title">Wound healing</h5> <p>None of the five studies included in this comparison reported on wound healing (<a href="./references#CD004179-bbs2-0001" title="LassenMR , GallusA , RaskobGE , PineoG , ChenD , RamirezLM , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. New England Journal of Medicine2010;363(26):2487‐98. NCT00423319 . Study of an investigational drug for the prevention of thrombosis‐related events following hip replacement surgery (ADVANCE‐3). https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&amp;rank=1 (accessed 30 August 2015). PineoGF , GallusAS , RaskobGE , ChenD , RamirezL‐M , RamacciottiE , et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. Journal of Thrombosis and Haemostasis2013;11(3):444‐51. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , LassenMR . Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. Blood. 2010; Vol. 116. RaskobGE , GallusAS , PineoGF , ChenD , RamirezLM , WrightRT , et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE‐2 and ADVANCE‐3 trials. Journal of Bone and Joint Surgery. British Volume2012;94(2):257‐64. ">ADVANCE 3</a>; <a href="./references#CD004179-bbs2-0005" title="AgnelliG , ErikssonBI , CohenAT , BergqvistD , DahlOE , LassenMR , et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thrombosis Research2009;123(3):488‐94. ">EXTEND Study</a>; <a href="./references#CD004179-bbs2-0011" title="Anon . Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. http://www.bayer.ca/2008. CohnDM , HermanidesJ , DevriesJH , KamphuisenPW , KuhlsS , HomeringM , et al. Stress‐induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. Thrombosis and Haemostasis2012;107(2):225‐231. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. Blood (ASH Annual Meeting Abstracts)2007;110(11):6. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). British Journal of Haematology2008;141(Suppl 1):82. ErikssonBI , BorrisLC , FriedmanRJ , HaasS , HuismanMV , KakkarAK , et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. New England Journal of Medicine2008;358(26):2765‐75. ErikssonBI , KakkarAK , TurpieAG , GentM , BandelTJ , HomeringM , et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. Journal of Bone and Joint Surgery. British Volume2009;91(5):636‐44. ErikssonBI , RosencherN , FriedmanRJ , HomeringM , DahlOE . Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis Research2012;130:147‐51. HaasS , BorrisLC , FriedmanRJ , HuismanMV , KakkarAK , GeertsW , et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). Pathophysiology of Haemostasis and Thrombosis2008;36(Suppl 1):A15. LassenMR , GentM , KakkarAK , ErikssonBI , HomeringM , BerkowitzSD , et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. Journal of Bone and Joint Surgery. British Volume2012;94(11):1573‐8. NCT00329628 . Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&amp;rank=1 (accessed 30 August 2015). RosencherN , LlauJV , MueckW , LoeweA , BerkowitzSD , HomeringM . Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). Acta Anaesthesiologica Scandinavica2013;57(5):565‐72. ">RECORD 1 Trial</a>; <a href="./references#CD004179-bbs2-0013" title="ErikssonBI , DahlOE , HuoMH , KurthAA , HantelS , HermanssonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE‐NOVATE II): A randomised, double‐blind, non‐inferiority trial. Thrombosis and Haemostasis2011;105(4):721‐9. HuoM , ErikssonB , DahlO , KurthA , HantelS , HermassonK , et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE‐NOVATE II randomised trial [Abstract No. 0564]. Haematologica2010; Vol. 92:233. NCT00657150 . Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE‐NOVATE&amp;rank=1 (accessed 30 August 2015). ">RE‐NOVATE II Trial</a>; <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a>). </p> </section> </section> <section id="CD004179-sec-0161"> <h4 class="title">Reporting bias, subgroup and sensitivity analysis</h4> <p>We did not construct funnel plots for meta analyses because the meta analyses did not include at least 10 studies. </p> <p>We planned to apply subgroup analysis to examine participants undergoing revisions of a previous hip or knee replacement or hip fracture repair, but we unfortunately found this to be impossible because these data were not reported separately. As the duration of the in‐hospital/initial phase ranged from four days to 14 days, subgroup analysis for 15 days or more was not required. Results of the other planned subgroup analyses are reported above. We did not consider any studies to be of low quality based on the 'Risk of bias' tool and therefore did not perform the planned sensitivity analysis for this reason. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004179-sec-0162" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004179-sec-0162"></div> <section id="CD004179-sec-0163"> <h3 class="title" id="CD004179-sec-0163">Summary of main results</h3> <p>We have shown that extended‐duration prophylaxis with DOACs in patients undergoing major hip or knee replacement surgery significantly reduces the risk of symptomatic VTE. This benefit is achieved with no excess adverse events or major bleeding but with increased minor bleeding. A significant reduction in PE or mortality could not be shown but the direction of the treatment effect for these outcomes was consistent with that seen for the primary outcome, suggesting that a similar reduction for these outcomes might be expected. </p> <p>Our findings of a significant treatment benefit of extended‐duration prophylaxis for prevention of symptomatic VTE are based on a pooled analysis of both hip and knee replacement trials. However, our meta‐analysis cannot draw a fully informed conclusion for participants undergoing knee replacement as far fewer studies evaluated these types of participants separately, as compared with hip replacement. </p> <p>When comparing extended‐duration anticoagulants (DOACs and VKA) versus extended‐duration LMWHs there were no differences between the treatments in symptomatic and asymptomatic VTE and showed decreased odds in total VTE for DOACs versus LMWH. There was also no difference in mortality, adverse events or bleeding events. These findings support the use of less invasive oral anticoagulants versus the more invasive LMWHs which often have to be administered by injection into subcutaneous tissue. However, it needs to be kept in mind that several of the meta‐analyses were underpowered and showed heterogeneity. We hope with the inclusion of new studies in future updates of this review we will be better able to draw stronger conclusions regarding these treatment comparisons. </p> <p>One widely recognised impediment to the more widespread use of effective prophylaxis in patients undergoing hip or knee replacement is concern about the risk of bleeding. In this regard, the data from our review are reassuring in that, even with sustained use for up to six weeks, prophylactic‐dose anticoagulants is not associated with an excess in major bleeding in all comparisons except for the comparison of VKA versus heparin. </p> </section> <section id="CD004179-sec-0164"> <h3 class="title" id="CD004179-sec-0164">Overall completeness and applicability of evidence</h3> <p>This review included a total of 16 studies with nearly 25,000 randomised participants. Despite this large number of included studies some comparisons included a single study only, or few events were recorded, which led to wide confidence intervals, and difficulties interpreting the data. </p> <p>There are other antithrombotic therapies besides the ones evaluated in this review that might be used for prevention of VTE in major orthopaedic surgery or out‐of‐hospital prophylaxis, for example aspirin, which were not addressed in this review. We plan to include these in future updates of this review. </p> <p>Although compliance with extended‐duration prophylaxis seemed to be 90% or higher in most trials included in our meta‐analyses, the definition of compliance varied among the studies and not all studies reported the level of compliance with randomised treatment allocation that was achieved. However, the probable impact of lack of compliance is to reduce the power of a randomised trial to detect a significant treatment benefit. Therefore an even greater benefit of extended‐duration prophylaxis might be realised in populations in which higher levels of compliance are achieved. </p> <p><a href="./references#CD004179-bbs2-0047" title="WangZ , AndersonFAJr , WardM , BhattacharyyaT . Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. PLoS ONE2014;9(4):e91755. [10.1371/journal.pone.0091755. eCollection 2014] ">Wang 2014</a> reported that surgical site infections and reoperations in the three months following joint replacements may be associated with anticoagulant use and this may be a barrier to extended thromboprophylaxis but our meta‐analyses are underpowered to draw conclusions on this issue due to a lack of reporting of wound infections, wound healing and reoperations in the studies included in this review. </p> </section> <section id="CD004179-sec-0165"> <h3 class="title" id="CD004179-sec-0165">Quality of the evidence</h3> <p>Despite examining the totality of the evidence by pooling results from all the available properly randomised trials, the total number of participants randomly assigned and the number of outcome events was modest. Therefore, our meta‐analyses potentially lacked statistical power to provide precise estimates of frequency and treatment effect for clinically important outcomes such as PE. However, DVT and PE represent clinical manifestations of the same underlying disease process. Therefore, strategies that are effective for the prevention of DVT, especially those proximally located, are likely also to be effective for the prevention of non‐fatal and fatal PE. </p> <p>There was a lot of variation in the design of studies included in our meta‐analyses. However, differences among trials are inevitable since individual trials look at different populations with different treatment protocols, and there is always some heterogeneity, even within individual trials (<a href="./references#CD004179-bbs2-0036" title="LauJ , IoannidisJP , SchmidCH . Summing up evidence: one answer is not always enough. Lancet1998;351(9096):123‐7. ">Lau 1998</a>; <a href="./references#CD004179-bbs2-0046" title="ThompsonSG . Why sources of heterogeneity in meta‐analysis should be investigated. BMJ (Clinical research ed.)1994;309(6965):1351‐5. ">Thompson 1994</a>). Differences in trial design do not necessarily preclude pooling of their results since, in a meta‐analysis, individual participants are directly compared only with other participants within the same trial, and not across the trials. The validity of our approach is further supported by the external consistency of our findings with the results of individual trials. </p> <p>The quality of the evidence varied by comparison and was on average moderate. Heterogeneity was found between studies comparing DOAC and heparin, and for some outcomes, such as PE and mortality, few events were recorded during the study periods leading to imprecision. For three comparisons, only one study was identified. See <a href="./full#CD004179-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD004179-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD004179-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD004179-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD004179-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD004179-tbl-0006">summary of findings Table 6</a> for further details. </p> </section> <section id="CD004179-sec-0166"> <h3 class="title" id="CD004179-sec-0166">Potential biases in the review process</h3> <p>Every effort was made to limit potential biases in the review through duplication of study selection, data extraction and assessment of risk of bias by two review authors. Also, we utilised pre‐designed data extraction forms and discussed any disagreements and undertook a meticulous and exhaustive search for both published and unpublished studies. </p> <p>Despite these techniques to reduce bias, there are still areas of concern. One issue was with the total numbers of participants used in the meta‐analyses. Most of the included studies had large numbers of participants that were excluded after randomisation. This was due mainly to detecting DVT at discharge from the hospital, non‐compliance, adverse events and non‐evaluable objective testing of DVT. Due to these large numbers of exclusions it was inappropriate to use all randomised participants, and we therefore attempted to use the most reliable intention‐to‐treat population as reported by the study authors. This method required us to adapt the numbers used by the study authors, which did vary between studies. </p> <p>We did not stratify according to the use of mechanical prophylaxis since, in most studies, the use of mechanical prophylaxis was left to the discretion of the local investigator and is usually not reported separately in the final study report. However, this should not lead to any bias because the use of mechanical methods is likely to be balanced between the two groups as a result of proper use of randomisation. </p> </section> <section id="CD004179-sec-0167"> <h3 class="title" id="CD004179-sec-0167">Agreements and disagreements with other studies or reviews</h3> <p>A recently published meta‐analysis evaluated extended duration using new oral anticoagulants versus extended duration using LMWHs (<a href="./references#CD004179-bbs2-0038" title="LiewA . Extended‐duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: A meta‐analysis of the randomized controlled trials. Journal of Thrombosis and Haemostasis2014;12(1):107‐9. ">Liew 2014</a>). The four included studies are also included in our review. For symptomatic VTE they found a risk ratio in favour of oral anticoagulants of 0.42 (95% CI 0.21 to 0.86). Although <a href="./references#CD004179-bbs2-0038" title="LiewA . Extended‐duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: A meta‐analysis of the randomized controlled trials. Journal of Thrombosis and Haemostasis2014;12(1):107‐9. ">Liew 2014</a> included <a href="./references#CD004179-bbs2-0014" title="ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkCN , FrostickSP , et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double‐blind, non‐inferiority trial. Lancet2007;370(9591):949‐56. ErikssonBI , DahlOE , RosencherN , KurthAA , VanDijkN , FrostickSP , et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW‐049). Journal of Thrombosis and Haemostasis2007;5(Suppl 2):OW‐049. NCT00168818 . Dabigatran etexilate in extended VTE prevention after hip replacement surgery. https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE‐NOVATE&amp;rank=2 (accessed 30 August 2015). ">RE‐NOVATE Trial</a> in their review, they did not include this study in the evaluation of symptomatic VTE, which led to the major differences in our findings, as the two dabigatran treatment groups had a large number of VTEs, compared with the LMWH group. <a href="./references#CD004179-bbs2-0038" title="LiewA . Extended‐duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: A meta‐analysis of the randomized controlled trials. Journal of Thrombosis and Haemostasis2014;12(1):107‐9. ">Liew 2014</a> also did not include the <a href="./references#CD004179-bbs2-0015" title="SamamaCM , VrayM , BarreJ , FiessingerJN , RosencherN , LecompteT , et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low‐molecular‐weight heparin with oral anticoagulant. Archives of Internal Medicine2002;162(19):2191‐6. ">SACRE Study</a>. <a href="./references#CD004179-bbs2-0038" title="LiewA . Extended‐duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: A meta‐analysis of the randomized controlled trials. Journal of Thrombosis and Haemostasis2014;12(1):107‐9. ">Liew 2014</a> found no difference in mortality or bleeding events, which is similar to our own review. </p> <p>A meta‐analysis published in 2001 compared extended‐duration prophylaxis to short duration followed by placebo or no treatment (<a href="./references#CD004179-bbs2-0028" title="EikelboomJW , QuinlanDJ , DouketisJD . Extended‐duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta‐analysis of the randomised trials. Lancet2001;358(9275):9‐15. ">Eikelboom 2001</a>). <a href="./references#CD004179-bbs2-0028" title="EikelboomJW , QuinlanDJ , DouketisJD . Extended‐duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta‐analysis of the randomised trials. Lancet2001;358(9275):9‐15. ">Eikelboom 2001</a> included nine studies, five of which were also included in our review and the other four we excluded because we deemed they did not meet the five‐week treatment‐duration requirement for this review. <a href="./references#CD004179-bbs2-0028" title="EikelboomJW , QuinlanDJ , DouketisJD . Extended‐duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta‐analysis of the randomised trials. Lancet2001;358(9275):9‐15. ">Eikelboom 2001</a>'s findings were similar to ours, with a decreased odds of symptomatic DVT in the extended duration treatment group (OR 0.38, 95% CI 0.24 to 0.61), no difference in major bleeding but an increase in minor bleeding. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD004179-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD004179-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD004179-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD004179-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 1 Symptomatic VTE (DVT and PE)." data-id="CD004179-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 2 Symptomatic DVT (proximal or distal)." data-id="CD004179-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 3 Symptomatic PE." data-id="CD004179-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 3 Symptomatic PE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic)." data-id="CD004179-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 5 Asymptomatic DVT." data-id="CD004179-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 5 Asymptomatic DVT.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 6 All‐cause mortality." data-id="CD004179-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 6 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 7 Adverse events." data-id="CD004179-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 7 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 8 Bleeding ‐ major." data-id="CD004179-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 8 Bleeding ‐ major.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 9 Bleeding ‐ minor." data-id="CD004179-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 9 Bleeding ‐ minor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Heparin versus placebo, Outcome 10 Reoperation." data-id="CD004179-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Heparin versus placebo, Outcome 10 Reoperation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin K antagonists versus placebo, Outcome 1 Symptomatic VTE (DVT and PE)." data-id="CD004179-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Vitamin K antagonists versus placebo, Outcome 1 Symptomatic VTE (DVT and PE). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin K antagonists versus placebo, Outcome 2 Symptomatic DVT (proximal or distal)." data-id="CD004179-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Vitamin K antagonists versus placebo, Outcome 2 Symptomatic DVT (proximal or distal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin K antagonists versus placebo, Outcome 3 Symptomatic PE." data-id="CD004179-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Vitamin K antagonists versus placebo, Outcome 3 Symptomatic PE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin K antagonists versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic)." data-id="CD004179-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Vitamin K antagonists versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin K antagonists versus placebo, Outcome 5 All‐cause mortality." data-id="CD004179-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Vitamin K antagonists versus placebo, Outcome 5 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin K antagonists versus placebo, Outcome 6 Adverse events." data-id="CD004179-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Vitamin K antagonists versus placebo, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Vitamin K antagonists versus placebo, Outcome 7 Bleeding ‐ major." data-id="CD004179-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Vitamin K antagonists versus placebo, Outcome 7 Bleeding ‐ major.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 1 Symptomatic VTE (DVT and PE)." data-id="CD004179-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 2 Symptomatic DVT (proximal or distal)." data-id="CD004179-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 3 Symptomatic PE." data-id="CD004179-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 3 Symptomatic PE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic)." data-id="CD004179-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 5 All‐cause mortality." data-id="CD004179-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 5 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 6 Adverse events." data-id="CD004179-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 6 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 7 Bleeding ‐ major." data-id="CD004179-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 7 Bleeding ‐ major.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 8 Bleeding‐ clinically relevant non‐major." data-id="CD004179-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 8 Bleeding‐ clinically relevant non‐major.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 9 Bleeding ‐ minor." data-id="CD004179-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 9 Bleeding ‐ minor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 10 Reoperation." data-id="CD004179-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 10 Reoperation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOAC versus placebo, Outcome 11 Wound infection." data-id="CD004179-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 DOAC versus placebo, Outcome 11 Wound infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 1 Symptomatic VTE (DVT and PE)." data-id="CD004179-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 1 Symptomatic VTE (DVT and PE). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 2 Symptomatic DVT (proximal or distal)." data-id="CD004179-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 2 Symptomatic DVT (proximal or distal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 3 Symptomatic PE." data-id="CD004179-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 3 Symptomatic PE. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic)." data-id="CD004179-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 5 Asymptomatic DVT." data-id="CD004179-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 5 Asymptomatic DVT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 6 Asymptomatic distal DVT." data-id="CD004179-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 6 Asymptomatic distal DVT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 7 All‐cause mortality." data-id="CD004179-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 7 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 8 Bleeding ‐ major." data-id="CD004179-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 8 Bleeding ‐ major. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vitamin K antagonists versus heparin, Outcome 1 Symptomatic VTE (DVT and PE)." data-id="CD004179-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Vitamin K antagonists versus heparin, Outcome 1 Symptomatic VTE (DVT and PE). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vitamin K antagonists versus heparin, Outcome 2 Symptomatic DVT (proximal or distal)." data-id="CD004179-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Vitamin K antagonists versus heparin, Outcome 2 Symptomatic DVT (proximal or distal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vitamin K antagonists versus heparin, Outcome 3 Symptomatic PE." data-id="CD004179-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Vitamin K antagonists versus heparin, Outcome 3 Symptomatic PE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vitamin K antagonists versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic)." data-id="CD004179-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Vitamin K antagonists versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vitamin K antagonists versus heparin, Outcome 5 All‐cause mortality." data-id="CD004179-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Vitamin K antagonists versus heparin, Outcome 5 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vitamin K antagonists versus heparin, Outcome 6 Bleeding ‐ major." data-id="CD004179-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Vitamin K antagonists versus heparin, Outcome 6 Bleeding ‐ major.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vitamin K antagonists versus heparin, Outcome 7 Bleeding ‐ minor." data-id="CD004179-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Vitamin K antagonists versus heparin, Outcome 7 Bleeding ‐ minor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Vitamin K antagonists versus heparin, Outcome 8 Reoperation." data-id="CD004179-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 Vitamin K antagonists versus heparin, Outcome 8 Reoperation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 1 Symptomatic VTE (DVT and PE)." data-id="CD004179-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 1 Symptomatic VTE (DVT and PE).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 2 Symptomatic DVT (proximal or distal)." data-id="CD004179-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 2 Symptomatic DVT (proximal or distal).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 3 Symptomatic PE." data-id="CD004179-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 3 Symptomatic PE.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic)." data-id="CD004179-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 5 Asymptomatic DVT." data-id="CD004179-fig-0052" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 5 Asymptomatic DVT.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 6 Asymptomatic proximal DVT." data-id="CD004179-fig-0053" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 6 Asymptomatic proximal DVT.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 7 Asymptomatic distal DVT." data-id="CD004179-fig-0054" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 7 Asymptomatic distal DVT.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 8 All‐cause mortality." data-id="CD004179-fig-0055" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 8 All‐cause mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 9 Adverse events." data-id="CD004179-fig-0056" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 9 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 10 Bleeding ‐ major." data-id="CD004179-fig-0057" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 10 Bleeding ‐ major.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 11 Bleeding ‐ clinically relevant, non‐major." data-id="CD004179-fig-0058" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 11 Bleeding ‐ clinically relevant, non‐major.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 12 Bleeding ‐ minor." data-id="CD004179-fig-0059" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 12 Bleeding ‐ minor.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 13 Reoperation." data-id="CD004179-fig-0060" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 13 Reoperation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004179-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/urn:x-wiley:14651858:media:CD004179:CD004179-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_t/tCD004179-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOAC versus heparin, Outcome 14 Wound infection." data-id="CD004179-fig-0061" src="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 DOAC versus heparin, Outcome 14 Wound infection.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/media/CDSR/CD004179/image_n/nCD004179-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD004179-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> heparin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with heparin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.59<br/> (0.35 to 1.01) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2329<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (12 to 33) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.73<br/> (0.39 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2019<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000<br/> (9 to 33) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.61<br/> (0.16 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1595<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (1 to 15) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.59<br/> (0.14 to 2.46) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2500<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 9) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant non‐major bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ minor<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 2.01<br/> (1.43 to 2.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2500<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>46 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88 per 1000<br/> (65 to 119) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, low number of events leading to imprecision of results<br/> <sup>2</sup> Downgraded by one level, some heterogeneity present (I<sup>2</sup> = 49%) leading to wide CIs </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004179-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> vitamin K antagonists<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin K antagonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.10<br/> (0.01 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 43) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.13<br/> (0.01 to 2.62) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 43) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.32<br/> (0.01 to 7.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 43) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 2.89<br/> (0.12 to 71.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no events recorded in placebo group</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant non‐major bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, results from a single study only so heterogeneity could not be assessed<br/> <sup>2</sup> Downgraded by one level, number of events small leading to wide CI and imprecision of results </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004179-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> DOAC<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DOAC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.20<br/> (0.06 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2419<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 8) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.18<br/> (0.04 to 0.81) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2459<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 7) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.25<br/> (0.03 to 2.25) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1733<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/> (0 to 10) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/> (0.06 to 16.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2457<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 1000<br/> (0 to 13) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding‐ clinically relevant non‐major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.22<br/> (0.76 to 1.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2457<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000<br/> (21 to 51) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ minor<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.18<br/> (0.74 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>2457<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/> (21 to 51) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DOAC:</b> direct oral anticoagulant; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, results from a single study so heterogeneity cannot be assessed<br/> <sup>2</sup> Downgraded by one level, low number of events leading to wide CI and imprecision of results </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004179-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> anticoagulant (chosen at investigators' discretion)<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with anticoagulant (chosen at investigators' discretion)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.50<br/> (0.09 to 2.74) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>557<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 38) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.33<br/> (0.03 to 3.21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>557<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (0 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.00<br/> (0.06 to 16.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>557<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (0 to 55) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 5.05<br/> (0.24 to 105.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>557<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no major bleeding recorded in the placebo groups</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinically relevant non‐major bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor bleeding<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, results from a single study so heterogeneity could not be assessed<br/> <sup>2</sup> Downgraded by one level, low number of events leading to wide CIs and imprecision of results </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004179-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> vitamin K antagonists<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin K antagonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.64<br/> (0.85 to 3.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1279<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/> (20 to 70) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.36<br/> (0.69 to 2.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1279<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>31 per 1000<br/> (16 to 60) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 9.16<br/> (0.49 to 170.42) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1279<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>no cases of symptomatic PE reported in the heparin study arm</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 3.87<br/> (1.91 to 7.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1272<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>58 per 1000<br/> (30 to 111) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding ‐ clinically indicated non‐major</p> <p>Treatment duration 28 ‐ 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>clinically indicated non‐major bleeding events not reported in single included study in this comparison </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ minor<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.33<br/> (0.64 to 2.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1279<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000<br/> (13 to 54) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VKA:</b> vitamin K antagonist; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level, single study so heterogeneity could not be assessed<br/> <sup>2</sup> Downgraded by one level, wide CI<br/> <sup>3</sup> Downgraded by one level, low number of events leading to imprecision of results </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD004179-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair<br/> <b>Setting:</b> hospital and outpatient setting<br/> <b>Intervention:</b> DOAC<br/> <b>Comparison:</b> heparin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with heparin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with DOAC</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic VTE (DVT and PE)<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.70<br/> (0.28 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15977<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000<br/> (1 to 8) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic DVT (proximal or distal)</p> <p>Treatment duration 28 ‐ 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.60<br/> (0.11 to 3.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15977<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (0 to 9) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Symptomatic PE<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.91<br/> (0.43 to 1.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>14731<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<br/> (1 to 4) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ major</p> <p>Treatment duration 28 ‐ 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.11<br/> (0.79 to 1.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16199<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000<br/> (7 to 13) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ clinically relevant, non‐major<br/> Treatment duration 28 ‐ 42 days </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 1.08<br/> (0.90 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>15241<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>33 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/> (30 to 42) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Bleeding ‐ minor</p> <p>Treatment duration 28 ‐ 42 days</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.95<br/> (0.82 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>11766<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>63 per 1000<br/> (55 to 72) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>DOAC:</b> direct oral anticoagulant; <b>DVT:</b> deep vein thrombosis; <b>OR:</b> odds ratio; <b>PE:</b> pulmonary embolism; <b>RCT:</b> randomised controlled trial; <b>VTE:</b> venous thromboembolism </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded by one level for inconsistency (heterogeneity, I<sup>2</sup> = 55%)<br/> <sup>2</sup> Downgraded by one level for imprecision due to low number of events leading to wide CI<br/> <sup>3</sup> Downgraded by one level for inconsistency (heterogeneity, I<sup>2</sup> = 65%) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/full#CD004179-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004179-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Heparin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic VTE (DVT and PE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.35, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.36, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.21, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Hip or knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptomatic DVT (proximal or distal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.39, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1296</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.41, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1595</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.16, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>872</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.24, 8.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total VTE (symptomatic and asymptomatic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2544</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.28, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.25, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.21, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Hip or knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.16, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Asymptomatic DVT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1304</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.24, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.21, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Hip or knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.19, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2518</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.31, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.11, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 15.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Hip or knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.69 [0.22, 98.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.68, 1.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.68, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Bleeding ‐ major <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.14, 2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.03, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.14, 7.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Hip or knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Bleeding ‐ minor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.43, 2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1494</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [1.53, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.58, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Hip or knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [0.11, 69.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Reoperation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Heparin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004179-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vitamin K antagonists versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic VTE (DVT and PE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptomatic DVT (proximal or distal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 7.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total VTE (symptomatic and asymptomatic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.01, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bleeding ‐ major <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [0.12, 71.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [0.12, 71.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Vitamin K antagonists versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004179-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DOAC versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic VTE (DVT and PE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.06, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.06, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptomatic DVT (proximal or distal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.04, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.03, 2.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total VTE (symptomatic and asymptomatic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.11, 0.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.11, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.07, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1733</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.07, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.74, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bleeding ‐ major <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Bleeding‐ clinically relevant non‐major <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.76, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.76, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Bleeding ‐ minor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.74, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.74, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Reoperation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Wound infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.46, 3.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.46, 3.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DOAC versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004179-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Anticoagulant (chosen at investigators' discretion) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic VTE (DVT and PE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.09, 2.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.09, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptomatic DVT (proximal or distal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.03, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total VTE (symptomatic and asymptomatic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.14, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.14, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Asymptomatic DVT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.13, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.13, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Asymptomatic distal DVT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.13, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.13, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Bleeding ‐ major <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.05 [0.24, 105.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Knee replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>557</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.05 [0.24, 105.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Anticoagulant (chosen at investigators' discretion) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004179-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Vitamin K antagonists versus heparin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic VTE (DVT and PE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.85, 3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.85, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptomatic DVT (proximal or distal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.69, 2.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.69, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.16 [0.49, 170.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.16 [0.49, 170.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total VTE (symptomatic and asymptomatic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.85, 3.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.85, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.07 [0.24, 105.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.07 [0.24, 105.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Bleeding ‐ major <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.87 [1.91, 7.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1272</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.87 [1.91, 7.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Bleeding ‐ minor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.64, 2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.64, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Reoperation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [0.99, 21.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [0.99, 21.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Vitamin K antagonists versus heparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004179-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">DOAC versus heparin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Symptomatic VTE (DVT and PE) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.28, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.28, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptomatic DVT (proximal or distal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.11, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15977</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.11, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Symptomatic PE <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.43, 1.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.43, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total VTE (symptomatic and asymptomatic) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.29, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.29, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Asymptomatic DVT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.19, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6559</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.19, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Asymptomatic proximal DVT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.46, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Asymptomatic distal DVT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.75, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2639</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.75, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.64, 4.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.64, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9908</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.88, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Bleeding ‐ major <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.79, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.79, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Bleeding ‐ clinically relevant, non‐major <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.90, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Bleeding ‐ minor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.82, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Reoperation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.34, 3.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.34, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Wound infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.46, 1.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Hip replacement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.46, 1.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">DOAC versus heparin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004179.pub2/references#CD004179-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004179.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004179-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD004179-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD004179-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD004179-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD004179-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD004179-note-0013">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004179\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004179\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004179\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004179\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004179\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jU9oKp1Y&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004179.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004179.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004179.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004179.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004179.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714425770"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004179.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714425775"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004179.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d6e604fa79377',t:'MTc0MDcxNDQyNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 